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Summary 
 
Although PfCRT has been implicated as the main factor affecting chloroqune 
accumulation and resistance in Plasmodium falciparum, quinine accumulation and 
resistance have long been suspected to be affected by more than one genetic factor. 
Prior studies demonstrated that reduced quinine accumulation did not necessarily 
cause increased quinine resistance (Sanchez et al., 2008b), indicating that 
resistance and accumulation did not share all factors affecting them.  
In this study, the initial accumulation levels of radio-labelled quinine in the progeny 
set of the HB3 x Dd2 genetic cross were investigated and quantitative trait loci (QTL) 
analysis was performed based on these data. By measuring the initial quinine 
accumulation, a read-out defined by processes contributing to early quinine 
accumulation, such as facilitating, transporting or partitioning processes, would be 
obtained, thereby isolating these processes from the later events that cause cell 
death, such as inhibition of haem mineralisation or of some enzymatic function. The 
IC90 data of the same progeny set (Ferdig et al., 2004) were reanalysed and 
comparing the QTL analysis data obtained from quinine initial accumulation and IC90 
levels allowed isolation of factors affecting only cell deaths from those that also 
affected drug transport. 
A novel locus in chromosome 7, B5M12, seems to have a major effect to both 
quinine accumulation and IC90. The locus acts synergistically with pfcrt. Two loci in 
chromosome 13, VAPA and C13M73, showed major effect on quinine IC90, but had 
no effect to the accumulation. Despite the prediction that the putative NA+/H+ 
exchanger (PfNHE) is involved in quinine resistance, the result revealed that the 
putative gene was not located within these two peaks. The Dd2 alleles of VAPA and 
C13M73 were associated with higher quinine IC90. The secondary scan showed the 
involvement of pfmdr1 in both quinine accumulation and IC90. Interestingly, the Dd2-
type pfmdr1 contributes to an increase in the initial quinine accumulation, and, 
correspondingly, to an increase in the sensitivity to quinine (the IC90 being 
decreased). 
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Zusammenfassung 
 
In Plasmodium falciparum gilt PfCRT seit langem als Hauptfaktor bei der 
Chloroquinakkumulation und –resistenz. Die Chininakkumulation und –resistenz 
scheint jedoch weit komplexer zu sein, und es wird vermutet, dass mehrere Faktoren 
hierbei eine Rolle spielen. Früherer Untersuchungen haben gezeigt, dass eine 
verminderte Chininakkumulation nicht zwingend mit einer höheren Resistenz 
einhergeht (Sanchez et al., 2008b), daher kann die Akkumulation von anderen 
Faktoren beeinflusst sein wie der Resistenz. 
In dieser Arbeit wurde die initiale Akkumulation von radioaktivem Chinin in den F1 
Nachkommen oder den parentalen Stämmen HB3 und Dd2 untersucht und 
anschließend eine QTL-Analyse („quantitative trait loci analysis“) der Daten 
durchgeführt. Da die frühe Chininakkumulation bestimmt wurde, erhält man einen 
Einblick in Prozesse wie dem erleichternden Transport und Kompartimentierung. 
Dadurch konnte man diese Prozesse von späteren Ereignissen, die den Zelltod 
durch die Inhibition der Hämmineralisierung oder anderer enymatischer Prozesse, 
trennen. IC90 Daten (Ferdig et al., 2004) der Stämme der selben Kreuzung wurden 
erneut analysiert und mit der QTL-Analyse der initialen Chininakkumulation 
verglichen. Hierbei konnten Faktoren, die den Zelltod beeinflussen von Faktoren die 
die frühe Akkumulation beeinträchtigen, separiert werden. 
Ein neuer Lokus auf Chromosom 7, B5M12, schien die Chininakkumulation und den 
IC90 zu beeinflussen. Dieser Lokus interagierte synergistisch mit pfcrt. Zwei Loki auf 
Chromosom 13, VAPA und C13M73, hatten einen bedeutenden Effekt auf den 
Chinin IC90 aber keinen Effekt auf die Akkumulation. Frühere Untersuchungen 
zeigten einen möglichen Einfluss des Na+/H+ Austauschers (PfNHE) auf den IC90, 
allerdings konnte die Lokalisation dieses Gens auf dem Chromosom nicht im 
Maximum nachgewiesen werden und besaß demnach nicht den höchsten „LOD-
Score“. Das Dd2 Allel von VAPA und C13M73 wurde mit erhöhtem Chinin IC90 in 
Verbindung gebracht. In einem zweiten Scan, ohne Berücksichtigung von pfcrt, 
konnte ein Einfluss von pfmdr1 auf die Akkumulation sowie auf den IC90 
nachgewiesen werden. Interessanterweise führte pfmdr1 von Dd2 zu einer erhöhten 
initialen Chininakkumulation und führte außerdem zu einer erhöhten 
Chininsensitivität, d.h. zu einem verringerten IC90 Wert. 
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1.  Introduction 
1.1. Malaria 
 
Malaria is caused by a protozoan parasite from the genus Plasmodium¸ which 
belongs to the Phylum: Apicomplexa; Class: Sporozoa; Order: Coccidia; Suborder: 
Haemosporidiae; Family: Plasmodiidae. There are more than 100 species of 
Plasmodium that can infect various animal species such as reptiles, birds and 
various mammals. However, only five species infect humans, Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and 
Plasmodium knowlesi, which is only recently known to infect human, as well as 
monkey, its conventional host (Cox-Singh et al., 2008, White, 2008). P. falciparum 
causes the majority infection in Africa and is responsible for most severe diseases 
and mortality. The least common malaria parasite is P. ovale, which is restricted to 
West Africa, while P. malariae is found worldwide, but also with relatively low 
frequency. The most widespread malaria parasite is P. vivax but infections with this 
species are rarely fatal (Tuteja, 2007). P. vivax and ovale form resting stages in the 
liver (hypnozoites) that, once reactivated, can cause a clinical relapse many months 
after the initial infection (Greenwood et al., 2005). The parasite is transmitted by 
female Anopheles mosquitos. Of approximately 400 species of Anopheles throughout 
the world, about 60 are natural malaria vectors, and 30 are of major importance 
(Tuteja, 2007).  
1.1.1. Malaria; the Origin and History 
 
DNA-sequencing studies show that P. falciparum originated 165 million years ago, 
probably in the Central Lakes area of Africa (Retief & Cilliers, 2006). Because of its 
intolerance of temperatures below 20ºC, it probably migrated to the Mediterranean 
area only after the last Ice Age, approximately 15,000-20,000 years ago. P. vivax and 
P. malariae probably originated in South-East Asia, and being tolerant of colder 
temperatures, possibly moved west at an earlier stage (Retief & Cilliers, 2006). 
The characteristic periodic fevers of malaria are recorded from every civilized society 
from China in 2700 BC through the writings of Greek, Roman, Assyrian, Indian, 
Arabic, and European physicians up to the 19th century. The earliest detailed 
accounts are those of Hippocrates in the 5th century BC, and thereafter there are 
increasing numbers of references to the disease in Greece and Italy and throughout 
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the Roman Empire as its occurrence became commonplace in Europe and 
elsewhere (Cox, 2002).  
The term malaria itself is derived from medieval Italian ‘mala aria’ meaning ‘bad air’ 
and was first used probably by Carnaro in a publication of 1440 (Retief & Cilliers, 
2006). The term came from early association of the disease with marshy areas. 
Theories regarding malaria’s miasmatic origins remained until late 19th century, 
when Charles Louis Alphonse Laveran in 1880 discovered the causative parasite in 
human blood (Retief & Cilliers, 2006) and Ronald Ross discovered that mosquitos 
transmitted the malaria (Tuteja, 2007). The complete sporogonic cycle of P. 
falciparum, P. vivax and P. malariae was demonstrated by Giovanni Batista Grassi 
and a team of Italian investigators including Amico Bignami and Giuseppe Bastianelli 
(Shortt, 1951). 
1.1.2. Malaria; the Global Impact 
 
Malaria is a global disease, affecting a large number of countries and causing a great 
deal of mortality and morbidity worldwide and throughout the history of mankind. It 
was estimated that in 2007, around 2.37 billion people, or about 35% of the world 
population, live in areas where there is some risk of P. falciparum transmission 
(Guerra et al., 2008). In the year 2006, there were an estimated 247 million cases of 
malaria occurred worldwide (World Health Organisation, 2008). Eighty six percent of 
these cases occurred in African regions, whereas 80% of the rests occurred in India, 
Sudan, Myanmar, Bangladesh, Indonesia, Papua New Guinea, and Pakistan (World 
Health Organisation, 2008). In the same year, approximately 881,000 deaths 
occurred from malaria, of which 91% were in Africa, which is a malaria high risk area 
(World Health Organisation, 2008).  
Figure 1.1. presents the global malaria distribution at the end of 2007. Although low-
risk areas cover a large number of people living across a wide geographical area, 
they produce a relatively small number of malaria cases each year, less than 2 
million, and account for less than 3% of cases reported by countries in 2006 (World 
Health Organisation, 2008). 
Malaria infection during pregnancy is a very serious public health problem in tropical 
and sub-tropical regions all over the world. In areas with low malaria transmission, 
adult women often do not have significant level of immunity to malaria that they 
become ill when infected with P. falciparum. In this area the risk of severe malaria is 
2-3 higher in pregnant women than in non-pregnant women. Maternal death may 
result directly from severe malaria or indirectly from malaria-related severe anaemia. 
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In addition, malaria may result in a range of adverse pregnancy outcomes, including 
low birth weight, spontaneous abortion, and neonatal death (World Health 
Organisation, 2003). In areas with high malaria transmission, adults normally have 
sufficient immunity against malaria that, even during pregnancy, P. falciparum 
infection does not usually result in fever or other clinical symptoms. The principal 
impact of malaria infection is malaria-related anaemia in the mother and the 
presence of parasites in the placenta, resulting impairment of foetal nutrition, which 
contributes to low birth weight and is a leading cause of poorer infant survival and 
development (World Health Organisation, 2003). In areas of Africa with high malaria 
transmission, P. falciparum infection during pregnancy is estimated to cause 10 000 
maternal deaths each year, 8% to 14% of all low birth weight babies, and 3% to 8% 
of all infant deaths (World Health Organisation, 2001). 
 
 
Figure 1.1. Global malaria distribution end 2007 (World Health Organisation, 
2008) 
The malaria distribution map shows malaria free countries and malaria endemic countries in 
phases of control, pre elimination, elimination and prevention of reintroduction. 
     Control 
 
 malaria-free and/or no on-going 
local transmission for over a decade
 
 
Elimination 
   
  Prevention of Introduction   Pre-elimination    
 
Malaria is also a major cause of disease and mortality of children. Every 40 seconds 
a child dies of malaria, resulting a daily loss of more than 2000 young lives all over 
the world (Sachs & Malaney, 2002). In 2006, it was still the fourth leading cause of 
deaths of children under five years old, after neonatal conditions, pneumonia and 
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diarrhoea and in 2007, 85% of malaria mortality were of children under 5 years old 
(World Health Organisation, 2009). The effect to children extends beyond mortality 
and morbidity, since malaria also reduces attendance to school and can impair 
intellectual development (Greenwood et al., 2005). 
In addition to the mortality and morbidity, there is also a strong correlation of malaria 
to the economy. This correlation is, however, complex and works both ways. Poverty 
sustains the conditions where malaria thrives, and malaria impedes economic growth 
and keeps communities in poverty (Sachs & Malaney, 2002). Recent studies to 
estimate the economic burden of malaria in endemic countries showed that the direct 
cost of one episode of malaria to a household was US$6.87 in Ghana,US$4.80 in 
Uganda, and US$4.50 in Mali (Teklehaimanot & Mejia, 2008). Cross country 
regressions over 25 years period (1965–1990) estimated that the annual economic 
growth of countries with intensive malaria is 1.3% less in comparison to countries 
where malaria is not endemic, even after controlling for factors such as initial poverty, 
economic policy, tropical location, and life expectancy. On the contrary, 10% 
reduction in malaria was associated with 0.3% higher growth (Gallup & Sachs, 2001). 
1.1.3. Clinical Manifestations 
 
The clinical disease can be categorised into uncomplicated and severe malaria, and 
the clinical manifestations might vary in the presentation and severity. ranging from 
no symptoms at all, fever, chill, flu-like symptoms (Malaria In Armenia, 2002), 
metabolic acidosis, hypoglicaemia kidney failures and comatose in severe and 
complicated malaria (Patel et al., 2003), severe anaemia (World Health Organisation, 
2001) and congenital malaria (Maitra et al., 1993) in cases of malaria during 
pregnancy. However, when diagnosed early enough and treated correctly, malaria 
can be handled relatively easily. 
The classical malaria attack lasts 6-10 hours. It consists of a cold stage (sensation of 
cold, shivering), a hot stage (fever, headaches, vomiting; seizures in young children), 
and finally a sweating stage (sweats, return to normal temperature, tiredness). 
Classically the attacks occur every second day with the "tertian" parasites (P. 
falciparum, P. vivax, and P. ovale) and every third day with the "quartan" parasite (P. 
malariae). Some of these symptoms are related to the release of TNF-α during 
schizonts release (Kwiatkowski et al., 1989). Parasite egress in P. falciparum is, 
however, often unsynchronised, leading to persistent spiking fever or daily fibril 
paroxysms (Rasti et al., 2004). 
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Severe malaria normally results from sequestration of the parasites to various 
organs, such as the heart, lung, kidneys, subcutaneous tissues and placenta (Miller 
et al., 2002). The sequestration occurs by interaction of parasites-derived proteins on 
the surface of infected red blood cells (RBCs) with certain molecules expressed on 
uninfected RBCs, endothelial cells as well as placental cells (Baruch, 1999). Several 
human proteins are implicated in the specific manifestations of malaria, for example 
chondroitin sulphate A (CSA), which plays role in parasites adhesion to placenta and 
intercellular adhesion molecule 1 (ICAM1) in cerebral malaria (Miller et al., 2002). 
Malaria is normally diagnosed using a combination of clinical observations, case 
history and diagnostic tests, principally microscopic blood examinations (Tuteja, 
2007). Thin blood film is normally used for routine estimation of parasitaemia, since it 
is easier to see and count the parasites and the blood. A thick blood film 
concentrates the layers of red blood cells (RBC) on a small surface by a factor of 20 
to 30 and provides enhanced sensitivity of the blood film technique. The sensitivity of 
the thick blood film procedure operated by an experienced technician is about 50 
parasites/µl of blood (assuming a total RBC count of 5 x 106/µl of blood), which is 
equivalent to 0.001% of infected RBC (iRBC) (Moody, 2002). A rapid diagnostic test 
(RDT) is also available, although expensive and most likely not affordable for most 
people living in the malaria endemic areas. The test is based on recognition histidine 
rich protein 2 (HRP2), lactose dehydrogenase (LDH) and aldolase (Moody, 2002). 
HRP2 is a water-soluble protein produced by asexual stages and young gametocytes 
of P. falciparum (Rock et al., 1987). It is expressed on the RBC membrane surface, 
and because of its abundance in P. falciparum, it is the first antigen used for RDT 
(Moody, 2002). pLDH, an enzyme found in the glycolytic pathway of the malaria 
parasite, is produced by sexual and asexual stages of the parasite (Makler et al., 
1998). Different isomers of pLDH for each of the four Plasmodium spp. infecting 
humans exist, and their detection constitutes a second approach to RDT 
development (Moody, 2002). Aldolase, which is also a glycolytic enzyme (Meier et 
al., 1992), have been suggested as target antigens for RDT for species other than P. 
falciparum (Moody, 2002).  
1.1.4. Life Cycle 
 
The life cycle of malaria parasites is extremely complex, involving alternating hosts, 
the invertebrate Anopheles mosquitoes and vertebrate humans. Due to this 
complicated life cycle, the parasites requires specialised protein expression for 
survival in both the invertebrate and vertebrate hosts, for both intracellular and 
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extracellular survival, for the invasion of a variety of cell types and for the evasion of 
host immune responses (Tuteja, 2007). 
Malaria in humans develops via two phases, an exoerythrocytic (hepatic) and an 
erythrocytic phase. The parasite life cycle is described in Figure 1.2.  
 
 
Figure 1.2. The life cycle of the malaria parasite in the human host and the 
mosquito vector. (Ersmark et al., 2006) 
The trophozoite stage in the erythrocytic cycle is enlarged. 
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The infectious stage sporozoites of Plasmodium residing in the salivary glands of the 
mosquitoes are injected to human during blood meal. Previously, it was thought that 
sporozoites move rapidly away from the site of injection as soon as they are injected 
to the human hosts. However, a recent study using rodent malaria parasites (P. 
yoelii) showed that, at least in this case, the majority of infective sporozoites remain 
at the injection site for hours, with only slow release into the circulation (Yamauchi et 
al., 2007). Once in the bloodstream, P. falciparum and P. malariae sporozoites reach 
the liver and enter the hepatocytes. where each sporozoite immediately develops into 
a tissue schizont containing 10,000–30,000 merozoites that will be released into the 
bloodstream by rupturing the schizonts. In P. vivax and ovale, however, some 
sporozoites turn into hypnozoites, a form that can remain dormant in the liver cells, 
causing relapses months or even years after the initial infection. P. falciparum and P. 
malariae lack this persistent liver stage.  
The mechanisms of hepatocytes invasion is not yet well understood, but studies have 
shown that a series of migration through several hepatocytes seem to be important 
for completion of the life cycle (Mota et al., 2001). The receptors on sporozoites 
responsible for hepatocyte invasion are mainly the thrombospondin domains on the 
circumsporozoite protein and on thrombospondin-related adhesive protein. The 
whole time taken to complete the tissue phase varies depending on the species; 8-25 
days for P. falciparum, 8-27 for vivax. 9-17 days for ovale, and 15-30 days for 
malariae (Tuteja, 2007). 
Merozoites released into the bloodstream again evade the host immune system by 
invading erythrocytes. The erythrocyte invasion process is complicated and involving 
several phases, initial recognition and reversible attachment of the merozoite to the 
erythrocyte membrane; reorientation and junction formation between the apical end 
of the merozoite (irreversible attachment) and the release of substances from the 
rhoptry and microneme organelles, leading to formation of the parasitophorous 
vacuole; movement of the junction and invagination of the erythrocyte membrane 
around the merozoite accompanied by removal of the merozoite’s surface coat; and 
resealing of the parasitophorous vacuole and erythrocyte membranes after 
completion of merozoite invasion (Miller et al., 2002) 
Asexual division starts inside the erythrocyte. Here, the parasites develop through 
different stages starting with the early trophozoíte stage known as the ring stage, 
where the parasites then enlarge accompanied by highly active metabolism including 
glycolysis of large amounts of imported glucose, ingestion of host cytoplasm and the 
proteolysis of haemoglobin into constituent amino acids. The end of the trophozoite 
stage is marked by multiple rounds of nuclear division without cytokinesis resulting in 
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the formation of schizonts. Each mature schizont contains around 20 merozoites and 
these are released after lysis of the RBC to invade further uninfected RBCs. This 
repetitive intraerythrocytic cycle of invasion–multiplication–release–invasion 
continues, taking about 48 h in P. falciparum, P. ovale and P. vivax infections and 72 
h in P. malariae infection. This release coincides with the sharp increases in body 
temperature during the progression of the disease.  
Several of the molecules involved in invasion are members of larger gene families 
Merozoite surface proteins (MSP)1 to MSP4 are integral membrane proteins 
identified on the surface of developing and free merozoites, which are involved in the 
initial recognition of the erythrocytes via interactions with sialic acid residues and are 
likely to be important for invasion because antibodies directed against these proteins 
can block this process (Cowman & Crabb, 2002). Erythrocyte binding antigen 175 
(EBA-175) is a P. falciparum protein binds the major glycoprotein (glycophorin A) 
found on human erythrocytes during invasion (Miller et al., 2002). The structure of 
EBA-175 has striking similarities to the Duffy antigen-binding proteins of P. vivax that 
are essential for successful invasion by this species. After invasion, the principal 
parasite ligand known as P. falciparum erythrocyte membrane protein 1 (PfEMP1), 
which is encoded by var multigene family, is expressed at the surface of the infected 
RBC (Chen et al., 2000). The extensive diversity in the var gene family is mainly 
responsible for the evasion of specific immune responses and many of these genes 
are expressed in the parasite population, but at any given time during an infection, 
parasites within infected cells express only a single var gene due to its unique gene 
activation and switching mechanism (Chen et al., 2000).  
The sexual cycle begins when a gametocyte is ingested during the bite of a female 
Anopheles mosquito. Depending on their sex, the gametocytes are transformed into 
male or female gametes in the gut of the mosquito. Gametes of the opposite sex 
merge to form diploid zygotes, which develop into ookinetes, which, in turn move to 
the mid-gut surface where they are converted into oocysts. Within the oocyst, several 
hundreds sporozoites are formed and later liberated to enable transport of the 
infectious sporozoites to the mosquito salivary glands. The mosquito is now able to 
transmit the infection during the next human bite, continuing the parasite life cycle 
(Ersmark et al., 2006). 
1.1.5. Chemotherapy 
 
Despite the consistent effort to develop a potent malaria vaccine, clinically proven 
vaccines are continuously absent that the prevention and treatment of disease still 
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has to rely on chemoprophylaxis and chemotherapy. However, since the discovery of 
the first synthetic antimalarial drug, chloroquine, during the 1930s, only a small 
number of substances have been proven to be suitable for licensing as drugs for 
human use, an to make the matter worse, there is a growing number of resistance to 
these compounds (Hyde, 2007). Thus, the repertoire of clinically valid and effective 
antimalarial drugs is really limited. 
Traditionally, antimalarial drugs are classified into the stages of parasite being 
targetted by the drugs, blood schizonticides acting on the asexual intraerythrocytic 
stages of the parasites, tissue schizonticides killing hepatic schizonts, and thus 
preventing the invasion of erythrocytes, acting in a causally prophylactic manner, 
whereas hypnozoiticides killing persistent intrahepatic stages of P. vivax and P. 
ovale, thus preventing relapses from these dormant stages, and gametocytocides 
destroying intraerythrocytic sexual forms of the parasites and preventing 
transmission from human to mosquito (Schlitzer, 2007). As there are no dormant liver 
stages in P. falciparum malaria, blood schizonticidal drugs are sufficient to cure the 
infection. In cases of P. vivax and P. ovale, a combination of blood schizonticides 
and tissue schizonticides is required. 
The first chemically synthesised and most commonly used drugs for malaria 
treatment and prophylaxis are from the quinoline group. All drugs in this group are 
derivatives of quinine, the active compound present in Chinchona bark and the oldest 
antimalaria known in the Western world. Despite the dissemination of resistant 
parasites all over the world in the last 40 years, chloroquine is up to now still the most 
important drug for prophylaxis and treatment of this disease, due to its safety, low 
cost and excellent activity (Wiesner et al., 2003). Primaquine, another member of 
quinoline group, has a unique spectrum of activity, including reliable efficacy to 
against primary and latent liver stages as well as gametocytes. Thus, although 
primaquine cannot be used to treat symptomatic malaria, the drug is used to 
eradicate hypnozoites of P. vivax and ovale, which are responsible for relapsing 
infections (Shapiro & Goldberg, 2005, Foley & Tilley, 1998). 
The second most commonly used drug after chloroquine is the antifolate combination 
sulfadoxin-pyrimethamin, or also known as fansidar (Wiesner et al., 2003). 
Antifolates work by inhibiting the folate biosynthesis of parasites. Humans depend on 
the dietary intake of pre-formed dihydrofolate as an essential nutrient, which is then 
reduced to tetrahydrofolate, and used in the biosynthesis of thymine, purine 
nucleotides, and several amino acids (Met, Gly, Ser, Glu, and His). On the other 
hand, Plasmodia can synthesise dihydrofolate from simple precursors as well as use 
exogenous dihydrofolate via a salvage pathway (Schlitzer, 2007). Dihydropteroate 
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synthase (DHPS) and dihydrofolate reductase (DHFR) are the two key enzymes 
used as targets of the antifolate drugs. DHPS is completely absent in humans, 
whereas protozoal DHFR is sufficiently different from the one of human that allow the 
development of selective inhibitors. The disruption of folate synthesis by DHFR and 
DHPS inhibitors leads to decreased levels of fully reduced tetrahydrofolate, which in 
turn decreases glycine to serine conversion, methionine conversion, and lower 
thymidylate levels with a subsequent arrest of DNA replication (Gregson & Plowe, 
2005). Antimalarial antifolate drugs, such as pyrimethamine, proguanil and the family 
of sulfa drugs, were introduced in the 1940s, but resistance arose rapidly, that it is 
necessary to use the drugs in combination therapy. Mutations in the genes pfdhfr and 
pfdhps are responsible for conferring resistance to this family of drugs (Gregson & 
Plowe, 2005) 
Artemisinin is derived from the ‘qing hao’ weed (Artemisia annua), or also known as 
‘sweet wormwood’ or ‘annual wormwood’, which has been used as traditional 
Chinese medicine to treat fever and symptoms of malaria since hundreds of years 
(Shapiro & Goldberg, 2005). The active ingredients of ‘qing hao’, called ‘qinghaosu’ 
and now known as artemisinin, was first extracted and crystallised in 1971 (Woodrow 
et al., 2005). Since then, an array of semi-synthetic artemisinin derivatives with 
improved potency and bioavailability has been developed, including 
dihydroarthemisinin, arthemeter and athesunate.  
Arthemisinins kill all species of Plasmodium that infect humans (Woodrow et al., 
2005) and active against both asexual and sexual blood stages, thus reducing 
transmission of the parasites (Schlitzer, 2007, Wiesner et al., 2003). The asexual 
stages are the most susceptible, with artemisinins decreasing the parasite biomass 
up to 10,000-fold per asexual cycle (Woodrow et al., 2005), making them the most 
active and rapid acting antimalarial drugs known today. In common with other 
antimalarials, artemisinins act predominantly against the large ring stage of infection 
when parasites are beginning to become most metabolically active, but, in contrast 
with other currently useful antimalarials, artemisinins also target tiny ring stages of 
infection present only a few hours after infection (Woodrow et al., 2005, Schlitzer, 
2007).  
The activity of artemisinins depends on the cleavage of endoperoxidase bridge 
presents in the middle of the substance by Fe+2, leading to formation of C-centred 
radicals. Previously it was thought that the C-centred radicals formation occurs in the 
food vacuole (FV), that the released radicals act more or less indiscriminately with 
different proteins, inhibiting multiple enzymes and preventing haem detoxification 
(Schlitzer, 2007). However, a more recent research suggested that the radicals 
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formation occurs in the cytoplasm catalysed by a cytoplasmic Fe+2 source, producing 
radicals acting specifically on a protein, called PfATP6, which is related to 
mammalian SERCA (Sarcoplasmic endoplasmic reticulum Ca+2 ATPase) (Eckstein-
Ludwig et al., 2003). 
Several antibiotics known to be active against bacteria also show activity against 
malaria. The activity depends on the presence of mitochondria and apicoplast that 
have their own DNA and bacteria-like machinery for replication, transcription, and 
translation. The mitochondrial genome is relatively small (6 kb), encoding only three 
proteins, whereas all other proteins and rRNAs have to be imported from the cytosol. 
The apicoplast genome is considerably larger (35 kb), including housekeeping genes 
responsible for the maintenance, whereas most proteins involved in the metabolic 
pathways are encoded in and imported from the nucleus (Schlitzer, 2007). Antibiotics 
like rifampicin is thought to inhibits the RNA synthesis in the apicoplast by inhibiting 
the RNA polymerase, whereas antibiotics like tetracycline, macrolides and 
lincosemides are considered to inhibit the protein synthesis in apicoplast (Wiesner et 
al., 2003, Schlitzer, 2007). 
1.2. Quinine 
 
Quinine (QN) is originally the plasmodicidal alkaloid present in the powdered bark of 
cinchona tree. As mentioned above, QN belongs to the quinoline group of drugs and 
due to its soluble character, QN is used mainly a intravenous formulation for 
treatment of complicated malaria, when oral medication is not possible (Wiesner et 
al., 2003).  
1.2.1. Quinoline drugs – The Discovery and History 
 
The quinolines represent one of the most successful yet poorly understood classes of 
drugs. Notable examples of the quinoline compounds include the 4-aminoquinoline 
chloroquine, the 8-aminoquinoline primaquine, and the quinolinemethanols 
mefloquine and QN. Until the emergence of drug-resistant parasites, these drugs 
were the most effective means to treat malaria. 
The bark of Cinchona officinalis had been the traditional medicine of the indigenous 
Peruvians to treat shivering. In 1633, an Agustinian named Calancha, of Lima, Peru, 
wrote that a powder of cinchona “given as a beverage, cures the fevers and tertians”. 
By 1640, cinchona was used to treat fevers in Europe. It was mainly distributed in the 
continent by the Jesuit monks and used in the form of powder, extract or infusion 
                                                                                                                     Introduction 
   14  
(Shapiro & Goldberg, 2005). In 1810 a crude mixture of crystalline alkaloids was 
extracted from cinchona bark by Gomes, in Portugal (Foley & Tilley, 1998) and in 
1820, QN, the active compound of the bark was first isolated by Pelletier and 
Caventou (Shapiro & Goldberg, 2005), making malaria one of the diseases treated 
with pure substance (Wiesner et al., 2003).  
In 1856 William Henry Perkin tried to synthesise QN, though unsuccessful. Instead, 
his effort led to the discovery of the first synthetic dye called ‘mauve’ (Schlitzer, 
2007), which later led to development to even more synthetic dyes. Microbiologists 
used these dyes for staining microorganisms, to enhance the visibility under 
microscope. Paul Ehrlich noticed that methylene blue was particularly effective in 
staining malaria parasites and rationalised that it could also be toxic to the parasite 
(Schlitzer, 2007). In 1891, Ehrlich and Guttmann cured two malaria patients with 
methylene blue, making this dye the first synthetic drug used to treat malaria 
(Wiesner et al., 2003, Schlitzer, 2007). 
In 1925 chemists at Bayer, in Germany, developed a new synthetic drug called 
plasmochin by modification of methylene blue. Clinical evaluation, however, showed 
that there were many side effects associated to this drug. A better tolerated 
congeneric drug called primaquine was introduced in 1956 (Schlitzer, 2007).  
Since the pathway for the synthesis of QN was not discovered until 1944 by 
Woodward and von Doering and the synthetic route was anyway too complex for 
commercial production, cinchona seeds were smuggled out from Peru and Cinchona 
plantations were established in Java, Indonesia by both the Dutch and the British. By 
1918, 102,000 kg of quinine was produced annually (Foley & Tilley, 1998).  
With the advent of World War I, and its campaigns in North Africa and Southern 
Europe, supplies of quinine were unable to meet the demands of the Allied and 
German armies. This situation had inspired further research in finding new 
antimalarials and in 1932 quinacrine was first introduced as an antimalarial drug 
(Schlitzer, 2007).  
Later, during the Pacific war campaign, the Allies were completely cut off from 
supplies of quinine when Indonesia was captured by the Japanese and quinacrine 
became the main drug for prophylaxis and treatment for the allied troops (Foley & 
Tilley, 1998, Schlitzer, 2007). Nowadays the drug is no longer used for malaria, due 
to its substantial side effect, such as the yellow staining of the skin and eyes, but still 
used for treatment of Giardia lamblia.  
A major success in the drug discovery happened in 1934 when resochin was found. 
Though after initial trials in Germany resochin was considered too toxic for human, 
resochin was later, after the war, re-evaluated and renamed as chloroquine (CQ) 
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(Schlitzer, 2007). CQ, then, largely replaced QN for prophylaxis and routine 
treatment.  
1.2.2. Haemoglobin Degradation 
 
During intraerythrocytic development, parasites degrade haemoglobin both to meet 
their nutrient demand and to counteract the osmotic imbalances caused by their own 
growth within the red blood cell (Lew et al., 2003). Haemoglobin is shuttled from 
erythrocytes to the food vacuole (FV) with a mechanism that is not yet fully 
understood. Some suggests that the haemoglobin is transported primarily via 
cytostomes (Lazarus et al., 2008), however some other mechanisms, such as 
internalisation of the host cell cytoplasm independent of actin polymerization, are 
also suggested recently (Elliott et al., 2008) Either in the FV or already in the 
cytostomes, the protein component of haemoglobin is digested by the successive 
action of various proteolytic enzymes, aspartic proteases plasmepsin (Plm) I, II, IV 
and the closely related histoaspartic protease (HAP), cysteine proteases (falcipain-1,-
2,-2’, and -3), a metalloprotease falcilysin, and the recently discovered dipeptidyl 
aminopeptidase 1 (DPAP1) (Ersmark et al., 2006). 
 
 
Figure 1.3. The general pathway for haemoglobin metabolism in P. falciparum 
(Ersmark et al., 2006). 
 
The precise sequence of events is still now a matter of controversy, especially 
whether a plasmepsin or a falcipain catalyzes the initial cleavage in the hinge region 
of the domain responsible for holding the native haemoglobin tetramer together. 
However, the general mechanism is shown in Figure 1.3. The cleavage unravels the 
protein, exposing it to subsequent cleavages into smaller peptides that can be 
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accomplished by both plasmepsins and falcipains. The metalloprotease falcilysin can 
only cleave small polypeptides, up to 20 amino acids, producing even shorter 
oligopeptides. DPAP1 was recently discovered to cleave off dipeptides from 
haemoglobin-derived oligopeptides in the food vacuole. Final hydrolysis to free amino 
acids is thought to occur in the parasite cytoplasm by aminopeptidases (Ersmark et 
al., 2006). 
The resulting small peptides and possibly free amino acids are transported across 
the vacuole membrane into the cytoplasm, leaving the haem part behind, leading to 
accumulation of large quantities of haem, which is toxic when accumulated at higher 
concentration in the FV, though the mechanisms of its toxicity remains unclear 
(Schlitzer, 2007). The parasite disposes this hazardous side product by 
biomineralising it to the inert haemozoin in the food vacuole (Egan et al., 2002), 
which is also known as the malaria pigment.  
 
 
Figure 1.4. Large quantities of haemoglobin are degraded in the food vacuole, 
yielding peptides and haem (Schlitzer, 2007) 
Haem, which is deposited as the insoluble polymer haemozoin, represents a harmful waste 
product to the parasite. CQ form complexes with FPIX which are toxic to the parasites. In 
chloroquine-resistant strains, the drug is expelled from the DV by the action of a membrane-
bound transporter (PfCRT). 
 
1.2.3. Chloroquine and Quinine – the Mechanism 
of Action 
 
Despite the overwhelming importance and its being the first drug used for treatment 
of malaria, the mechanisms of action of QN is not well understood. It is generally 
believed that QN mechanism of action is similar to that of CQ. Just like CQ, QN can 
inhibit haem biomineralisation (Hawley et al., 1998). Similar to CQ, incorporation of 
radiolabelled QN into the growing haemozoin polymers is almost completely arrested 
haem-CQ 
haem 
haemoglobin
haemoglobin
PfCRT
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in the presence of an inhibitor of plasmepsin I, an enzyme responsible for the initial 
cleavage of haemoglobin, suggesting that the interaction of both drugs with the haem 
monomer or polymer is central to activity (Mungthin et al., 1998). In addition, 
quantitative trait loci (QTL) analysis showed that QN and CQ shared at least one 
inheritable resistance determinant (Ferdig et al., 2004), despite QN being active 
against several CQ resistant P. falciparum strains. 
CQ, QN and other quinolines are thought to inhibit haem biomineralisation by forming 
a complex with haem (Hawley et al., 1998, Mungthin et al., 1998). A more recent 
publication suggests that QN forms an intramolecular salt bridge with haem, 
interrupting formation of the haemozoin precursor dimmer (de Villiers et al., 2008). 
The precise mechanism by which this toxic effect is exerted remains to be elucidated 
(Schlitzer, 2007). According to the new theory, the haem–CQ complex acts on a yet 
undefined membrane target, either impairing the membrane function directly, or 
triggering the release of Ca2+ ions resulting in the premature fusion of the transport 
vesicles shuttling haemoglobin to the FV. In these prematurely fused vesicles, 
haemoglobin is no longer properly degraded (Schlitzer, 2007).  
In chloroquine sensitive (CQS) strains the concentration of CQ in FV can reach 
20,000 times higher than that in the extracellular medium (Sanchez et al., 2007). 
Since CQ presents in the FV as a diprotic, amphiphilic base, some early studies 
suggested that the drug was retained in the FV due to pH gradient between FV and 
parasite cytoplasmic pH (Yayon et al., 1985), however a more recent publication 
shows that the FV pH in CQR and CQS strains are relatively comparable (Kuhn et 
al., 2007). 
1.2.4. Chloroquine and Quinine – the Resistance 
 
The first signs of CQ resistance appeared almost simultaneously in southeast Asia 
and South America around 1960 (Hartl, 2004). Its continual use for treatment and 
prophylaxis increased the selection pressure for emergence of resistance, and since 
the first confirmed case CQ resistant P. falciparum malaria was reported in 1979 
(Campbell et al., 1979), more and more cases were reported subsequently from 
different parts of the world (Sansonetti et al., 1985, Le Bras et al., 1986, Weniger et 
al., 1982) until it becomes a worldwide problem nowadays. 
QN, on the other hand, has been spared from widespread or prolonged use that high 
level resistance to the drug has been very slow to develop (Foley & Tilley, 1998). 
Unfortunately, a decrease of QN dose responsiveness in P. falciparum infection in 
South East Asia, South America and Africa (Bloland, 2001, Pukrittayakamee et al., 
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1994, Segurado et al., 1997, Jelinek et al., 1995) as well as the detection of field 
isolates with increased QN IC90 (Mayxay et al., 2007) have been reported. This 
phenomena is very worrying since QN is up to now still the main medication used for 
the treatment of severe and complicated malaria (World Health Organisation, 2008). 
QN and CQ were predicted to have similar, if not the same, mechanism of action 
(Mungthin et al., 1998, Hawley et al., 1998), although QN often remains active 
against some CQ resistant parasites. QTL analysis also shows that QN resistance 
shares at least one genetic determinant with CQ resistance, that is pfcrt (P. 
falciparum chloroquine resistant transporter), a gene located in chromosome 7 of P. 
falciparum genome (Ferdig et al., 2004). 
 
 
Figure 1.5. Topology of PfCRT (Valderramos & Fidock, 2006) 
Predicted structure and representative haplotypes of P. falciparum chloroquine resistance 
transporter. (A) PfCRT is predicted to have ten transmembrane domains (Bray et al., 2005) 
(B) pfcrt allelic variants 
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PfCRT, the gene product of pfcrt, is a putative drug metabolite carrier having ten 
transmembrane domains (TMDs) (Figure 1.5.) (Bray et al., 2005, Martin & Kirk, 2004) 
located at the FV membrane (Fidock et al., 2000). It is unsure, however, whether the 
protein acts as a carrier (Sanchez et al., 2007) or a pore (Bray et al., 2006).  
Mutations within pfcrt is associated with CQ resistance (Sidhu et al., 2002, Fidock et 
al., 2000, Lakshmanan et al., 2005), altered susceptibility to CQ and QN (Cooper et 
al., 2007, Lakshmanan et al., 2005, Johnson et al., 2004) and altered responsiveness 
to other antimalarial drugs (Johnson et al., 2004). The most well studied mutation 
within the pfcrt gene is the K76T substitution. The K76T related CQ resistance is 
reversed by the presence of verapamil (Martin et al., 1987, Wellems et al., 1990) and 
removal of this mutation abolishes the CQ resistance and its verapamil reversibility 
(Lakshmanan et al., 2005).  
In comparison to the chloroquine sensitive (CQS) strains, the chloroquine resistant 
(CQR) strains of P. falciparum accumulate much less chloroquine (Bray et al., 1998, 
Cooper et al., 2007), keeping the intracellular concentration of CQ below toxic level.  
The reduced CQ accumulation has been genetically linked to pfcrt (Fidock et al., 
2000, Lakshmanan et al., 2005, Sidhu et al., 2002) and explained by a verapamil 
sensitive CQ efflux system (Wellems et al., 1990, Martin et al., 1987). In the case of 
QN, reduced accumulation of QN does not always correlate to increased QN 
resistance (Sanchez et al., 2008b), however, all strains having K76T mutated pfcrt 
show increased verapamil-sensitive QN efflux (Sanchez et al., 2008b). 
In addition to pfcrt, there is another gene often associated with quinine resistance, 
that is pfmdr1 (Plasmodium falciparum multi drug resistance 1), which is located in 
chromosome 5. The pfmdr1 gene encodes for a P-glycoprotein (P-gp) transporter 
called PfMDR1 or also known as Pgh-1, which is expressed during the 
intraerythrocytic stage. PfMDR1 consists of two homologous halves, each 
conataining six transmembrane domains (TMDs) (Figure 1.6.) (Peel, 2001). In 
bacteria and tumour cells, P-gp is often associated with verapamil-reversible multiple 
drug resistance (Valderramos & Fidock, 2006), since the protein is capable of 
extruding a wide range of structurally and functionally unrelated cytotoxic agents 
(Borges-Walmsley et al., 2003). P-gp transporters belong to ABC (ATP Binding 
Cassette) transporter superfamily. 
PfMDR1 is localised mainly in the food vacuolar membrane (FVM) (Cowman et al., 
1991), with its ATP binding site facing the cytoplasm (Karcz et al., 1993). The protein 
is expressed at approximately equal levels in CQ resistant and sensitive isolates 
suggesting that over expression of PfMDR1 is not essential for CQ resistance 
(Cowman et al., 1991). However, mutation of pfmdr1 at amino acids 86, 184, 1034, 
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1042 and 1246 contribute to in vitro resistance to QN, mefloquine, chloroquine and 
artemisinin resistance (Sidhu et al., 2005, Reed et al., 2000), especially N1042D 
substitution that seems to play an important role in QN resistance (Sidhu et al., 
2005). Decreasing the copy number increases susceptibility to QN (Sidhu et al., 
2006) and vice versa (Cowman et al., 1994), suggesting the involvement of the gene 
in QN resistance.  
 
 
Figure 1.6. Predicted structure of PfMDR1 (Valderramos & Fidock, 2006).  
(a) PfMDR1 has two homologous halves, each with six predicted transmembrane domains 
and a nucleotide-binding pocket (Peel, 2001). The nucleotide-binding domains (NBD1 and 
NBD2; orange boxes) are each formed by large cytoplasmic domains. (b) Representative 
haplotypes, including the one most commonly associated with amplification of pfmdr1 copy 
number. 
 
On the contrary to the afore mentioned findings, QTL analysis of QN IC90 performed 
by Ferdig et al. (Ferdig et al., 2004) showed no direct correlation between QN IC90 
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and pfmdr1, neither in the primary, nor in the secondary scan. In addition, a recent 
finding also shows that pfmdr1 polymorphism does not contribute to net QN 
accumulation (Sanchez et al., 2008b).  
Another group shows linkage between pfmdr1 and the FV staining pattern of Fluo-4, 
a fluorescein acetoxymethyester (AM) derivative that have been used widely in 
imaging and in surrogate assay of P-gp function (Rohrbach et al., 2006). In the same 
publication, it is also shown that several antimalarial drugs, including QN, can 
compete the Fluo-4 accumulation in the FV in chloroquine resistant strains but not in 
chloroquine sensistive strains (Rohrbach et al., 2006). 
1.3. Quantitative Trait Loci (QTL) Analysis 
 
A complex, or quantitatively inherited trait, or a quantitative trait is a trait determined 
by numerous genes and might have complicated relationship with the environment 
(Wu et al., 2007). Each gene involved gives a little but additive contribution to a trait 
and in most cases the genes effects are also influenced by the environment. 
Classical examples of such traits are human height variation, which is affected by 
health and diet as well as genetic potential. 
The ‘molecular dissection’ of quantitative traits had been discussed even before the 
demonstration of DNA as the hereditary factor, due to the observation that many 
traits showed ‘blending inheritance’ accounted from combination of several 
Mendelian factors and environmental modifying effects (Paterson, 1995). Even in 
early 20th century, association between a discrete trait or a marker with a 
continuously variable character was already noted (Sen & Churchill, 2001, Paterson, 
1995).  
The principle of QTL mapping is pretty simple; traits co-segregate with chromosomal 
regions carrying alternative alleles that influence the phenotype (Sen & Ferdig, 
2004). Though not necessarily genes themselves, QTL are stretches of DNA closely 
linked to the genes underlying the respective trait. However, until the last decade the 
mapping principle has not been employed very extensively since most of genetic 
maps contained too few genetic markers to allow precise mapping of quantitative trait 
loci (QTL) to specific chromosomal locations (Paterson, 1995). Genetic markers are 
DNA sequence polymorphisms located at a specific location in the genome that show 
Mendelian inheritance (Wu et al., 2007). The first genetic marker used for genomic 
mapping and population studies was the restriction fragment length polymorphisms 
(RFLP) (Wu et al., 2007). 
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Genetic linkage occurs when particular genetic loci or alleles for genes are inherited 
jointly. Genetic loci on the same chromosome are physically connected and tend to 
stay together during meiosis, and are thus genetically linked. Because there are 
crossing overs of DNA when the chromosomes segregate, alleles on the same 
chromosome can be separated and go to different daughter cells.  
QTL are mapped by linkage disequilibrium with molecular markers that do exhibit 
Mendelian segregation (Mackay, 2001). If a QTL is genetically linked to a marker 
locus, they will tend to be inherited together, that the frequency of the marker and the 
QTL inherited together in the offspring will be higher. The higher the percentage of 
descendants that does not show both traits, the further apart on the chromosome 
they are.  
The distance between markers is expressed in centi Morgan (cM). When the 
distance between two loci, or two markers, or a locus and a marker, is 1 cM, then the 
recombination frequency (θ) between them is 1%, which means that in every 100 
meiosis events, one recombination occurs between the two loci (or two markers, or 
between the marker and the locus). When two loci are not linked, or segregate 
independently, the θ value will be 50%. This is a consequence of independent 
assortment as described in the Mendel’s second law (Wu et al., 2007). Thus, linked 
genes have θ value less than 50% or are separated by a distance less than 50 cM. 
Linkage between Mendelian traits (or between a trait and a marker, or two markers) 
is usually expressed as a LOD (Logarithm of Odds) score. The LOD score is the log 
base ten of the likelihood ratio comparing the likelihood of observing the phenotype 
when the two loci are linked and the likelihood of observing the phenotype when the 
two loci are not linked (Sen & Ferdig, 2004). 
1.3.1. QTL Mapping of P. falciparum 
 
The availability of P. falciparum Dd2xHB3 (Wellems et al., 1990) genetic cross of 
through the Malaria Research and Reference Reagent Resource Center (MR4), and 
the segregation map of all progeny through the NCBI 
(http://www.ncbi.nlm.nih.gov/Malaria/Mapsmarkers/PfSegData/segdata.html) (Su et 
al., 1999, Su et al., 1997, Walker-Jonah et al., 1992) provides tools for QTL analysis 
of the parasite. Since HB3 is a CQS strain with wild type pfcrt gene, whereas Dd2 is 
a CQR strain having mutated pfcrt gene, the availability of the progeny set allows 
closer analysis in the factors playing roles in drug, especially quinolines, 
accumulation, mechanism and resistance. 
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The presence of only small number of progeny (35 were published, but only 34 were 
available during this project), however, affects the sensitivity of the QTL analysis, 
allowing only for detection of small number of loci with large effects. Bringing down 
the threshold level, of course, will allow detection of more loci, but it will also 
compromise the stringency of the analysis (Sen & Ferdig, 2004). 
Despite these drawbacks, there are advantages of the system, including the 
availability of completely sequenced genome (3D7 strain), small genome size (24 
Mb; 1 gene/5kb) consisting of 14 nuclear chromosomes, and a fully genotyped, 
mapping population with corresponding MS linkage map demonstrating high, uniform 
recombination at an average resolution of one cross-over every 45 kb and one 
mapped marker approximately every 25 kb (Sen & Ferdig, 2004). 
1.3.1.1. P. falciparum Genetics System 
 
In almost all of its life, P. falciparum genome is haploid. Only within the mosquito 
midgut, when mature male and female gametes emerge from infected erythrocytes 
and fuse to form a zygote, commences the brief diploid phase of the parasite. Within 
three hours after fertilisation, meiosis occurs and the parasite develops into an 
ookinete that crosses the midgut wall and grows into oocyst. During the oocyst stage, 
mitotic division occurs, producing thousands of sporozoites that break out and travel 
by the haemolyph to the mosquito salivary gland. Together with the mosquito’s 
saliva, the sporozoites are injected to the human bloodstream. 
Due to its haploid genome, for mapping purpose, P. falciparum malaria cross can be 
treated like the backcross of two inbred line diploid organisms. As illustrated in Figure 
1.7., in diploid organisms such as mouse, when two homozygous parental strains are 
crossed, identical F1 progeny will be produced. Due to crossing over events, the loci 
originating from the other parent (black bars) segregate when this F1 progeny is 
backcrossed to one of the parental strains (white bars). 
In the parasite, diploid zygote produced by fertilisation grows into an ookinete, which 
then undergoes meiosis. Due to crossing over during meiosis, haploid recombinant 
oocysts, which eventually grow into sporozoites that infect humans, are produced. 
Thus, unlike diploid organisms that have to undergo two sexual generations before 
the segregating alleles can be observed, haploid parasites yields unique haploid 
recombinant in a single sexual generation. 
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Figure 1.7. Genetic crossing schemes for generating mapping populations 
(Sen & Ferdig, 2004). 
Unlike diploid organisms that have to undergo two sexual generations before the segregating 
alleles can be observed (A), haploid parasites yields unique haploid recombinant in a single 
sexual generation (B). In a mouse (A); parental strains (black and white bars) are crossed to 
produce genetically identical F1 progeny which are crossed to one of the parental strains. 
Because of crossovers leading to the formation of the maternal gametes (black bars) the 
maternal alleles from the F1 are segregating. Each scheme generates a mapping populations 
(arrows) with two genotype classes that segregate 1:1 at each marker (m1-m3). 
 
1.3.1.2. More Than One Gene Involved in Quinoline Drug 
Responses 
 
Reports of steady gradual decrease of antimalarial drugs sensitivity from all over the 
world suggest that the mechanism of quinoline resistance involves more than one 
factor affecting the sensitivity trait (van Vugt et al., 1998, White et al., 1999, 
Pukrittayakamee et al., 1994). In addition, field studies also show that there are cross 
resistances between drugs in certain areas (Bloland, 2001) suggesting that the 
character shares molecular determinants (Sen & Ferdig, 2004).  
The evidences from the laboratories also seem to support the clinical data. The 
hallmark of a quantitative trait is its continuous distribution in the population. Sen and 
Ferdig show in their publication that the distribution of CQ IC90 values of Dd2, HB3 
and the F1 progeny of Dd2xHB3 cross illustrates the classical single gene Mendelian 
inheritance, with its typical bimodal distribution in the population (Sen & Ferdig, 
2004), although obviously there are variations within CQS and CQR strains. The QN 
IC90, on the other hand shows typical continuous distribution as observed in 
quantitative trait (Figure 1.8.). 
In another publication, Ferdig et al. show by QTL analysis that CQ and QN share at 
least one determinant, pfcrt (Ferdig et al., 2004). Resistance within this gene is 
known to alter susceptibility to CQ and QN (Cooper et al., 2007, Lakshmanan et al., 
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2005, Johnson et al., 2004) and altered responsiveness to other antimalarial drugs 
(Johnson et al., 2004). In addition to pfcrt as the common determinant, Ferdig et al. 
also suggested the involvement of other factors in chromosome 6, 9 and 13 in the 
QN resistance (Ferdig et al., 2004). 
 
 
Figure 1.8. Drug response distributions in the HB3xDd2 cross (Sen & Ferdig, 
2004).  
Frequency histograms showing the number of clones (y-axis) and the quantitative dose 
responses (y-axis) to chloroquine (A) and quinine (B). The bimodal shape for CQ indicates a 
major gene is controlling the trait; the unimodal distribution for QN is typical of a quantitative, 
multi-gene trait. 
 
1.3.2. Mapping of Quantitative Trait Loci (QTL) By 
Linear Regression Method 
 
Several methods for QTL mapping have been described in the literature. Amongst 
them is the linear regression method (Haley & Knott, 1992), which was applied in this 
project. This method uses regression analysis, analysis of regression variance (F-
test) and t-test of multiple markers. These statistical tests are performed solely on a 
single DNA information. Thus, basically in this test, linkage between a single DNA 
information and a phenotypic trait is analysed (Wu et al., 2007). Calculation is 
performed based on phenotypic means and variances within each marker. Therefore, 
a complete genetic map is actually not essential for the analysis, though, as 
performed in this project, marker analysis can be extended to include all markers in 
the genome (Wu et al., 2007). 
In this project, QTL analysis was performed using progeny from Dd2xHB3 cross 
(Wellems et al., 1990, Kirkman et al., 1996), of which the markers are already 
published previously (Walker-Jonah et al., 1992, Su et al., 1999, Su et al., 1997). 
Correlation between each marker to the QN accumulation or IC90 values of the 36 (34 
progeny and 2 parental) strains was analysed. 
A B
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When a phenotypic value y of an individual i, is affected by a locus z, then the 
relationship between the phenotypic character to a locus can be expressed in linear 
regression model as follows: 
yi = µ + zi α + ei, 
where µ is the overall mean, α is the correlation coefficient, which determines the 
genetic effect of the locus to the phenotype and ei is the random error (Wu et al., 
2007), which in this project was assumed to be 0. Applying this model, to the 
Dd2xHB3 cross segregation data, zi was defined as: 
 zi = 1 if pfcrt gene is inherited from Dd2 
 zi = 0 if pfcrt gene is inherited from HB3 
The correlation coefficient of a locus or α is then determined by Pearson regression 
(r) of the 0's and 1's of the locus against the phenotype of all strains, which is the 
measured values of uptake or IC90, to yield the correlation coefficient for that locus. 
If a QTL is linked to a marker, there will be a difference in the mean values of the 
quantitative trait amongst individuals having different alleles at the marker (Mackay, 
2001). In this project, the significance of the locus genetic effect was tested by 
calculating, with the appropriate degrees of freedom, the regression variance (F) 
ratio, and hence the corresponding p value. The position giving the best fit gives the 
most likely position of a QTL and the best estimates of its effect (Haley & Knott, 
1992). 
The difference in trait phenotype between individuals having different alleles at a 
marker is larger, when the QTL is closer to the marker locus, and reaching maximum 
when the marker locus coincides exactly with the QTL (Mackay, 2001). To determine 
the most likely position of the QTL, a modification of likelihood ratio test as described 
previously by Lander and Botstein (Lander & Botstein, 1989) can be used to give the 
LOD score value. In this project, the likelihood ratio of a locus was calculated as the 
logarithm of the ratio between the p value of the corresponding locus with the mean 
of the p values of the entire markers used. 
LOD score = -log10(pz/pave), 
where pz is the p value of locus z and pave is the mean of p values of the entire 
markers. The pz value of 100 times less than pave was taken as being significant. 
1.4. Aim of the Study 
 
Parasites with reduced sensitivity to QN is an emerging problem for the world health 
authorities, since QN is up to now still the main medication used for the treatment of 
severe and complicated malaria (World Health Organisation, 2008). Although no real 
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QN resistant strains have been discovered so far, decreased QN dose 
responsiveness in P. falciparum infection in South East Asia, South America and 
Africa (Bloland, 2001, Pukrittayakamee et al., 1994, Segurado et al., 1997, Jelinek et 
al., 1995) and discovery of field isolates with increased QN IC90 (Mayxay et al., 2007) 
have been reported. 
Many studies have been carried out to find genes involved in QN accumulation and 
resistance, although a recent publication shows that reduced accumulation of QN 
does not always correlate to increased QN resistance (Sanchez et al., 2008b). Ferdig 
et al. had identified some loci contributing to quinine response variation using QTL 
analysis of QN IC90 data of the Dd2xHB3 cross progeny set (Ferdig et al., 2004). 
These loci include pfcrt, which is located in chromosome 7, a loci in chromosome 5, 
which was thought to be linked to pfmdr1, and also a loci in chromosme 13, which 
was thought to be related to pfnhe (Ferdig et al., 2004).  
Although IC90 assay has been widely used to study drug response in Plasmodium, it 
is a measure of cell proliferation inhibition after 72 hours exposure to a drug. Thus, it 
may not only be affected by drug transport, but also other factors such as drug 
affinity to its target. Most cells, however, accumulate drugs within minutes of 
exposure to the drugs, thus, affected only by the transport mechanisms. Therefore, it 
was hypothesised that measuring the initial QN accumulation will lead to obtaining a 
readout defined by processes contributing to early quinine accumulation, whilst 
eliminating the effect of other processes causing cell death, such as inhibition of 
enzyme function. Thus, factors specifically affecting the transport of QN can be 
determined, hence complementing what have been found previously by Ferdig et al. 
(Ferdig et al., 2004). 
After several positive loci were located through the QTL analysis, mathematical 
analysis was also performed to investigate the interactions between some of these 
loci. In addition, bionformatics analysis was also carried out to find candidate genes 
lying within the positive loci. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Equipments 
 
Analytical scales  Sartorius, Göttingen 
Autoclave  Tuttnauer Systec 2540, Wettenberg 
Camera, DC 120 Zoom digital  Kodak, New York 
Centrifuges   
Biofuge fresco  Heraeus Instruments, Hanau 
Biofuge pico  Heraeus Instruments, Hanau 
J2-MC  Beckman, Krefeld 
L-60 Ultracentrifuge  Beckman, Krefeld 
Megafuge 1.0R  Heraeus Instruments, Hanau 
Megafuge 2.0R  Heraeus Instruments, Hanau 
RC5BPlus  Sorvall, Langenselbold 
Computer-software   
Adobe Photoshop® 5.0  Adobe Systems Inc, USA 
EndNote 8.0.2  ISI Research Soft, CA, USA 
Internet Explorer  Microsoft Communication Corp., CA USA 
MS Powerpoint  Microsoft Corporation, CA USA 
MS Word 98  Microsoft Corporation, CA USA 
SigmaPlot 9.01  Systat Software Inc. 
DNA- electrophoresis apparatus  Biorad, München 
Freezer -80ºC, UF85-300S  Heraeus GmbH, Hanau 
Freezers -20ºC  Liebherr, Biberach 
Fridges  Liebherr, Biberach 
Gas burner gasprofi 1 micro  WLD-TEC 
Ice machine AF 30  Scotsman, Milano, Italy 
Incubator (P. falciparum)  Heraeus Instruments 
Liquid nitrogen tank  Air Liquide, Ludwigshafen 
TRI-CARB 2100 TR liquid 
scintillation counter 
 Packard 
VarioMACS, MACS system  Miltenyi Biotec, Bergisch Gladbach 
Magnetic stirrer  Heidolph, Schwabach 
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Microscopes:   
Light optical microscope 
Axiolab 
 Zeiss, Jena 
Leica DMIL Light Microscope  Leica 
Microwave oven  AEG, Nürnberg 
Multipipette  Eppendorf, Germany 
PCR-machines:   
T gradient Thermocycler  Biometra, Göttingen 
GeneAmp PCR system 9700  AppliedBiosystems, CA USA 
pH-meter pH 537  WTW, Weilheim 
Pipetman Gilson P10; P20; P200; 
P1000 
 Abimed, Langenfeld 
Pipetus- akku  Hirschmann Labortechnik, Eberstadt 
pipetus® standard  Hirschmann Labortechnik, Eberstadt 
Power supply: Power Pac 300  Biorad, München 
Printer hp LaserJet 1300  Hewlett Packard, Heidelberg 
Rotor JA20.1  Beckman instruments, Inc., Palo Alto, CA, 
USA 
Spectrophotometer UVIKON 923  Kontron Instruments, 
Sterile work bench Herasafe  Heraeus Instruments, Hanau 
Stop watch  Roth, Karlsruhe 
Thoma Counting Chamber  Marienfeld, Germany 
UV-table UV-Transilluminator  Gibco BRL, Karlsruhe 
Vortex Genie 2  Roth, Karlsruhe 
Waterbath Julabo 7A  Julabo Labortechnik, Seelbach 
2.1.2. Disposables 
 
Aluminium foil  Roth, Karlsruhe 
Centrifuge tubes, Polypropylen-
18/95 
 Greiner Bio-one, Frickenhausen 
Clingfilm Saran  Dow Chemical Company, Schwalbach 
Coverslips for haemocytometer  Roth, Karlsruhe 
Cryovials  Nalgene®, Wiesbaden 
Cuvettes  Saarstedt, Nümbrecht, Germany 
Eppendorf tubes  Saarstedt, Nümbrecht, Germany 
Falcon tubes (15 ml; 50 ml)  Corning incorporation, Bodenheim 
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Gloves  Hartmann, Heidenheim 
Immersion oil  Zeiss, Jena 
Kimwipes lite 200  Kimberly Clark 
MACS-columns CS  Miltenyi Biotec, Bergisch Gladbach 
Object slides  Marienfeld, Lauda-Königshofen 
Multipipette tips   
Eppendorf Combitips 1.25 ml  Eppendorf, Germany 
Eppendorf Combitips 5 ml  Eppendorf, Germany 
Parafilm  American International CanTM, USA 
PCR softtubes 0.25 ml  Biozym Scientific, GmbH. 
Petri dishes (10 ml diameter)  Greiner Bio-one, Frickenhausen 
Petri dishes (25 ml diameter)  Greiner Bio-one, Frickenhausen 
Pipette tips  Corning Inc., Bodenheim 
Plastic pipettes (1 ml; 2 ml; 5 ml; 10 
ml; 25 ml) 
 Corning Inc., Bodenheim 
Radioactive Vials   
Mini PolyQ vials 6ml Beckman Instruments Inc., USA 
Saarstedt scintillation vials 20 
ml 
Saarstedt, Nümbrecht, Germany 
Sterile filters (0,2 µm)  Millipore GmbH, Ashburn 
Sterile filtration devices  Corning incorporation, Bodenheim 
Thermo well PCR tubes  Corning incorporation, Bodenheim 
2.1.3. Chemicals 
2.1.3.1. Non Radioactive Chemicals 
 
The non radioactive chemicals used in this study are from the firms Roth, Merck, 
Sigma, Serva and Applichem and were ordered directly or through the chemical 
facility of the University of Heidelberg medical faculty. 
2.1.3.2. Radioactive Chemicals 
 
The [3H]-chloroquine and [3H]-quinine (20.0 Ci mmol-1) used for this project were 
purchased from American Radiolabeled Chemicals. 
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2.1.4. Biological Materials 
2.1.4.1. Parasite Strains 
 
All parasite strains used in this study were received from the Malaria Research and 
Reference Reagent Resource Center (MR4), USA. 
 
Dd2  chloroquine resistant (CQR) parental strain 
HB3  chloroquine sensitive (CQS) parental strain 
B1SD  progeny of Dd2 and HB3 cross 
QC13  progeny of Dd2 and HB3 cross 
QC01  progeny of Dd2 and HB3 cross 
B4R3  progeny of Dd2 and HB3 cross 
SC05  progeny of Dd2 and HB3 cross 
TC08  progeny of Dd2 and HB3 cross 
GC03  progeny of Dd2 and HB3 cross 
3BA6  progeny of Dd2 and HB3 cross 
1BB5  progeny of Dd2 and HB3 cross 
3BD5  progeny of Dd2 and HB3 cross 
SC01  progeny of Dd2 and HB3 cross 
QC34  progeny of Dd2 and HB3 cross 
QC23  progeny of Dd2 and HB3 cross 
TC05  progeny of Dd2 and HB3 cross 
GC06  progeny of Dd2 and HB3 cross 
D43  progeny of Dd2 and HB3 cross 
C188  progeny of Dd2 and HB3 cross 
C408  progeny of Dd2 and HB3 cross 
CH3-116  progeny of Dd2 and HB3 cross 
CH3-61  progeny of Dd2 and HB3 cross 
7C3  progeny of Dd2 and HB3 cross 
7C7  progeny of Dd2 and HB3 cross 
7C12  progeny of Dd2 and HB3 cross 
7C16  progeny of Dd2 and HB3 cross 
7C20  progeny of Dd2 and HB3 cross 
7C46  progeny of Dd2 and HB3 cross 
7C111  progeny of Dd2 and HB3 cross 
7C126  progeny of Dd2 and HB3 cross 
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7C140  progeny of Dd2 and HB3 cross 
7C159  progeny of Dd2 and HB3 cross 
7C170  progeny of Dd2 and HB3 cross 
7C183  progeny of Dd2 and HB3 cross 
7C421  progeny of Dd2 and HB3 cross 
7C424  progeny of Dd2 and HB3 cross 
2.1.4.2. Enzymes and DNA Markers 
 
ApoI Restriction enzyme  New England BioLabs, Schwalbach 
EuroTaq DNA-polymerase   BioCat, Heidelberg 
1 kb Plus DNA-ladder  GibcoBRL, Karlsruhe 
2.1.4.3. Oligonucleotides  
 
All primers were purchased from Thermo Electron GmbH (Ulm). 
2.1.4.3.1. Fragment Length Polymorphisms 
 
The primers used to determine fragment length polymorphisms were designed by Dr. 
J. Mu of NIH based on highly polymorphic microsattelite regions of P.falciparum 
genome. The microsattelites and primers sequences used to detect the 
polymorphisms were listed in Table 2.1. 
 
Table 2.1. Microsattelites and primer sequences used to detect fragment length 
polymorphisms within the microsattelites. 
The combinations of the fragment length polymorphisms were used to identify the progeny of 
Dd2xHB3 cross used in the project. 
Microsattelites Forward Primers Reverse Primers 
C1M4 5’-atatcctacaacggtaagca-3’ 5’-ttctttttgaggagtaatgt-3’ 
C1M67 5’-acaggatttttgaagaaaaag-3’ 5’-taggataaatgtagctttag-3’ 
C4M62 5’-gaattcacttaaatgtatttatttg-3’ 5’-atgaagttatccattcgttt-3’ 
C13M13 5’-gttataagtatagcagacga-3’ 5’-atacattacggtattttaaa-3’ 
C13M63 5’-agagatactatgattatttta-3’ 5’-atattacaaagcttactacc-3’ 
C14M17 5’-acacaaagagaataggtata-3’ 5’-tagtaattctagtttaccta-3’ 
B5M124 5’-taataagtgtaagaaatatgga-3’ 5’-ataaaacagagcaaaataaag-3’ 
B5M5 5’-taaataatacaactactaatga-3’ 5’-attgatccatatttatatctc-3’ 
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2.1.4.3.2. Nested PCR of K76T PfCRT 
 
Whenever the length polymorphisms were not sufficient for strain validation, nested 
PCR detection of K76T PfCRT (Djimde et al., 2001) was employed. The primers 
used in the nested PCR reactions were listed in Table 2.2. 
 
Table 2.2. Sequences of primers used in the nested PCR as described by 
Djimde and colleagues (Djimde et al., 2001) 
 Forward Primers Reverse Primers 
1st PCR CRTP1: ccgttaataataaatacacgcag CRTP2: cggatgttacaaaactatagttacc 
2nd PCR CRTD1: tgtgctcatgtgtttaaactt CRTD2: caaaactatagttaccaattttg 
2.1.5. Buffers, Media and Solutions 
 
Cell culture medium  10% Human serum 
0.2 µg/ml Gentamycin 
0.1 mM Hypoxanthine 
in RPMI 25 mM HEPES L-Glutamine (Gibco) 
   
Freezing Solution   28% Glycerol (v/v) 
3% D-Sorbitol 
0.65% NaCl in ddH2O 
filter sterilised, kept at 4ºC 
   
Glucose solution for QN 
accumulation experiments 
 500 mM Glucose 
filter sterilised 
   
MACS buffer  1x PBS 
2 mM EDTA 
0.5% BSA 
   
Oil solution  Dibutylphtalate:Octylphtalate = 5:4 
   
RPMI Media pH 7.4 at 4ºC 
and 37ºC for QN 
accumulation experiments 
 GIBCO Powder RPMI 1640 + L-Glutamine+ 25mM 
HEPES + NaHCO3 pH to 7.4. at temperature 4ºC or 
37ºC in 1000 ml H2O 
filter sterilised 
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Sorbitol Solution  5% (w/v) D-sorbitol in ddH2O 
filter sterilised 
   
TAE   40 mM Tris-acetate 
1 mM EDTA  
   
TE Buffer  10 mM Tris/HCl pH 8.0 
1 mM EDTA 
   
Thawing solution I  12% NaCl, autoclaved 
   
Thawing solution II  1.6% NaCl, autoclaved 
   
Thawing solution III  0.9% NaCl / 0.2% glucose 
filter sterilised 
   
TKM1 Solution  10 mM Tris pH 7.6 
10 mM KCl 
10 mM MgCl2 
2 mM EDTA (pH 8.0) 
   
TKM2 Solution  10 mM Tris pH 7.6 
10 mM KCl 
10 mM MgCl2 
2 mM EDTA (pH 8.0) 
0.4 M NaCl 
   
Tissue solubiliser  50% (v/v) Tissue Solubiliser in Ethanol 
2.2. Methods 
2.2.1. Cell Culture 
2.2.1.1. In Vitro Culture of Plasmodium falciparum 
 
The erythrocytic stage of P. falciparum clones Dd2, HB3 and their 34 progeny (Ferdig 
et al., 2004, Wellems et al., 1990) were maintained in continuous blood culture as 
previously described (Trager & Jensen, 1976). The parasites were cultured in A+ 
human erythrocytes of approximately 5% haematocrit in either 10 cm or 25 cm 
diameter petri dishes containing 15 ml or 35 ml HEPES buffered RPMI medium, 
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respectively, supplemented with 10% heat inactivated A+ human serum, 200 µM 
hypoxanthine and 20 µg/ml gentamycin. The cultures were incubated in an 
atmosphere of 3% CO2, 5 % O2, 92 % N2, and 95% humidity at 37°C. The medium 
was changed every other day and the parasitaemia was determined using Giemsa-
stained blood smear. Whenever the parasitaemia reached 5-10%, the cultures were 
passaged to avoid parasites death due to lack of nutrient and accumulation of toxic 
metabolites in the medium. 
2.2.1.2. Preparation of Human Serum and Erythrocytes 
 
All erythrocytes and serum used in the project were received from the German Red 
Cross blood bank, Heidelberg. The human serum was aliquoted to 50 ml falcon 
tubes. 800 µl sterile 1 M CaCl2 was added to each tube, and the tubes were 
incubated at 37ºC for 30 min and then at 4ºC overnight. The tubes were centrifuged 
(4000 rpm, 30min) on the following day to pellet the fibrin, and then incubated at 
56ºC for 30 min to inactivate the serum. The serum was stored at -20ºC until needed. 
The concentrated erythrocytes were also aliquoted to 50 ml falcon tubes. To each 
tube 10 ml of RPMI medium was added, and the tubes were centrifuged (2300 rpm, 4 
min, without break). The erythrocytes were then kept at 4ºC and used within 1-2 
weeks. 
2.2.1.3. Counting Erythrocyte with Thoma Counting 
Chamber 
 
To determine the concentration of the enriched throphozoites cultures used in the QN 
accumulation experiments, a Thoma counting chamber was used. Before using the 
haemocytometer, the surfaces of the counting chamber and the coverslip had to be 
carefully cleaned with Kimwipes®. Then, a thin film of water vapour was formed on 
the surfaces by blowing wet air over them. The two surfaces were then pressed 
together to stick them, and then left to dry at room temperature. The culture used for 
counting had to be diluted enough not to allow the cells to be on top of one another 
that it might cause counting error. In addition, the cells had to be uniformly 
distributed. When the chamber was ready, the properly diluted sample of culture was 
introduced into it and the erythrocytes were counted using the 0.0025 mm2 squares 
located in the middle of the counting grid. Counting was performed under microscope 
with 10x objective lens. Since there are two counting grids in the counting chamber, 
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the average of the counted number of erythrocytes in each grid was taken for 
calculation. 
2.2.1.4. Calculating Erythrocyte Concentration 
 
As mentioned above, the area of each tiny square in the counting grid is 0.0025 mm2, 
whereas the depth of the chamber with the presence of a coverslip is 0.1 mm. So the 
volume of each square is 2.5x10-4 mm3.  
 
 A. 
 
 B. 
 
Figure 2.1. Thoma counting chamber (Rice University, 2007) 
(A) Mounting a haemocytometer (B) The counting grid. The erythrocytes were counted using 
the 0.0025 mm2 squares located in the middle of the counting grid.  
 
In each Thoma counting chamber, there are two counting grids. Since there are 256 
little squares in each counting grid, the number of erythrocytes per ml or mm3 is 
determined as: 
N x 4000 
256 
where N is the average number of erythrocytes counted in each counting grid. 
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2.2.1.5. Preparing Giemsa-Stained Slide of P. falciparum 
 
To determine culture’s parasitaemia and parasite developmental stage, slide with thin 
film of blood culture was made by spreading 50 µl of culture evenly onto the surface 
of a clean microscope slide, air dried, fixed in 100% methanol for 30 sec, and then 
again air dried. Fixed cells were then stained for 5-10 min in a solution of 10% 
Giemsa, washed with water and allowed to dry. 
2.2.1.6. Determining Parasitaemia 
 
The parasitaemia is defined as the percentage of P. falciparum infected erythrocytes 
and is determined by examining Giemsa-stained blood slide under light microscopy 
with 100x objective using immersion oil. The numbers of infected and uninfected 
erythrocytes were counted in ten consecutive field, considering the multiple infection 
as a single parasite. The parasitaemia was then calculated with the formula:  
(Number of parasites / Number of erythrocytes) X 100 = parasitaemia (%) 
2.2.1.7. Freezing Parasites 
 
Since the percentage of ring stage parasite will affect how fast the culture will revive 
after thawing, a culture containing at least 5% rings is normally used for freezing. 
First of all, most of the medium had to be removed from the plate. The culture was 
then centrifuged for 2 minutes at 1900 rpm and room temperature. The supernatant 
was then removed and the pellet was resuspended in equal volume of sterile freezing 
solution and mixed gently. Then, the 1 ml mixture was aliquoted into each of 2 ml 
cryotubes and snap frozen in ethanol/dry ice slurry for 15 minute before transferred 
to -80ºC freezer. For longer storage, the tubes were places in liquid nitrogen tank. 
2.2.1.8. Thawing Parasites 
 
After being removed from the liquid nitrogen, the cryotube containing parasites was 
warmed up for 2 min in a 37ºC water bath or in the palm of a hand to thaw the 
content. Then the content was transferred to a 15 ml falcon tube and 200 µl 12% 
NaCl per ml of blood was added to the tube at a rate of 2 drops per second, with 
constant, gentle mixing. Then, 9 ml 1.6% NaCl was added in the same way. The 
mixture was then centrifuged at 1900 rpm for 2 min, and the supernatant was 
decanted. Then, 7 ml 0.9% NaCl/0.2% glucose solution was added dropwisely to the 
pellet, whilst mixing it gently. Again the mixture was centrifuged at 1900 rpm for 2 min 
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and the supernatant was decanted. The pellet was then resuspended in complete 14 
ml parasite medium and transferred to a small petri dish and 0.5 ml fresh blood was 
then added to the culture. The culture was then kept in parasite incubator for at least 
two days before the medium was changed to allow the newly thawed-parasite to 
revive. All solutions were pre-warmed to 37°C before starting the thawing procedure. 
2.2.1.9. Synchronisation with Sorbitol 
 
Sorbitol treatment causes osmotic lysis of late stage trophozoites (Lambros & 
Vanderberg, 1979) due to the presence of an induced transport pathway in the 
erythrocyte membrane that is permeable to sorbitol and absent in ring stage 
parasites. Whenever a synchronised throphozoite culture was required for an 
experiment, synchronisation was performed approximately 16-18 hours prior to the 
experiment. To start the synchronisation of 35 ml culture with 5% haematocrit, the 
medium was removed from the plate and the blood was resuspended in 10 ml pre-
warmed, filter sterilised 5% D-Sorbitol solution and transferred to a 15 ml falcon tube. 
The tube was then incubated for 10 min at 37ºC before centrifuged for 2 min at 1900 
rpm RT. The pellet was then washed with 10 ml complete medium before 
resuspended in 33 ml medium and returned to the plate. 
2.2.1.10. Magnetic Cell Sorting (MACS) Purification 
 
To obtain trophozoites culture with approximately 95-97% parasitaemia for QN 
accumulation experiment, 5% trophozoite infected-culture was passed through a 
magnetic column prior to being used for the experiment. This method makes use of 
the paramagnetic property of haemozoin in the parasite, in comparison to the dia-
magnetic oxyhaemoglobin in red blood cell (Uhlemann et al., 2000). During its intra-
erythrocytic life cycle, Plasmodium parasite digests haemoglobin leaving haem, 
which is paramagnetic, as a by product. Haem is biomineralised into haemozoin in 
the food vacuole. Thus, when passed through magnetic column, trophozoites and 
schizonts stage infected erythrocytes were retained in the column, whereas 
uninfected and ring stage infected RBC passed unaffected. Prior to usage, the MACS 
column was fixed to the adapter and mounted to the magnetic field following the 
manufacturer’s instruction. Then, the matrix was equilibrated with MACS buffer 
before the culture was applied. The stopcock at the bottom of the column had to be 
adjusted in such a way that it allowed slow steady flow of culture through the column.  
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Then, while still applying the magnetic field, the column was washed with 
approximately two column volumes of MACS buffer or until the effluent is colourless, 
to ensure washing out of non-paramagnetic cells. The trophozoites and schizonts 
stage infected RBC were obtained by eluting them with MACS buffer from the column 
while the magnetic field was released. The eluate was then centrifuged (1900 rpm for 
2 min at room temperature) to harvest the cells and ready for the subsequent 
experiment. 
 
Figure 2.2. Magnetic Cell Sorting (MACS) Purification (Vogt, 2008) 
(A) Assembly of MACS column (B) Three different positions of the stopcock: liquid flows from 
the syringe to the column (left), from the column to the needle (middle), and stop position (no 
flows of liquid) (right). 
 
2.2.2. Strains Validations 
2.2.2.1. Genomic DNA (gDNA) Isolation from P. falciparum 
 
For the isolation of genomic DNA from P. falciparum, it was recommended to use a 
culture containing mature parasitic stages (trophozoites and schizonts), which would 
A 
B 
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give more DNA in comparison to ring stage parasites. The method described here 
was used to extract genomic DNA from 35 ml culture with 5% haematocrit.  
2.2.2.1.1. Erythrocyte Lysis 
 
Medium was removed by pipetting or centrifugation, then, the cells were 
resuspended with TKM1 solution to 30 ml. The suspension was then placed in 2x15 
ml falcon tubes. 150 µl 10% Saponin was added to each of the tube. The mixtures 
were mixed by gently inverting the tubes repeatedly until erythrocyte lysis occured. 
Once lysis had occurred, tubes were placed for 5 min on ice. Then the tubes were 
centrifuged for 8 min at 3800 rpm 4ºC in a pre-cooled centrifuge. The supernatants 
were then decanted and pellets were redissolved in TKM1 (equal volume used as 
before). The tubes were then re-centrifuged as previously, then the supernatants 
were decanted and the pellets were kept in -20ºC until required.  
2.2.2.1.2. gDNA Extraction 
 
150 µl TKM1 was added to a frozen parasite pellet. The mixture was vortexed to 
ensure pellet was properly dissolved, then 2.4 ml TKM2 was added and the mixture 
was further vortexed before the addition of 150 µl 20% SDS. The mixture was again 
vortexed before incubated for 15 min at 56ºC. Transfer mixture to 12 ml centrifuge 
tube (Greiner Polypropylen-12/75 centrifuge tube), then 1.35 ml 4 M NaCl was added 
and suspension was mixed properly by inverting the tube repeatedly. Then, the tube 
was centrifuged (Beckman JA20.1 rotor) for 10 min at 4ºC 11500 rpm. The 
supernatant was transferred to a new tube and two volumes of 100% ethanol was 
added. The solution was mixed thoroughly by inverting the tube before the tube was 
kept overnight at -20ºC. On the following day, the tube was centrifuged (Beckman 
JA20.1 rotor) for 30 minute at 4ºC 11500 rpm to pellet the DNA. The supernatant was 
then decanted, whereas the pellet was washed with 500 µl 70% ethanol and 
centrifuged for 5 min. The DNA pellet was then dried and resuspended in water or TE 
buffer. 
2.2.2.2. Detection of Fragment Length Polymorphisms 
 
The genome of P. falciparum contains highly polymorphic regions that may be PCR 
amplified and used to identify the strains (Anderson et al., 1999, Su et al., 1999, Su & 
Wellems, 1996). In the progeny of Dd2xHB3 cross, these regions were inherited from 
either one of the parents and the polymorphism patterns were used for strains 
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validation. Eight different primer pairs (sequences provided by Dr. Mu, MR4) were 
used for the PCR amplifications. The annealing temperatures used in the PCR 
reactions differ from one primer pairs to the other. The amplicons were run either in 
3% normal agarose gel or 2% MetaPhor® gel. 
 
PCR of Microsatellites for Detection of Fragment Length Polymorphisms 
25 µl PCR reaction  
Euro-Taq buffer (10x)        2.5 µl 
dNTPs (10 mM)                 0.5 µl 
Forward primer (50 µM)         0.5 µl 
Reverse primer (50 µM)          0.5 µl 
MgCl2 (50 mM)   1.25 µl 
Template gDNA   1 µl 
Euro-Taq DNA-Polymerase            0.25  µl 
H2O     18.5 µl 
Primers Anneling Temperature PCR Reaction 
C1M4 59ºC 95ºC 4’ 
C1M67 55°C 95ºC 45“
C4M62 59ºC 55°C or 59ºC 45“
C13M13 55°C 68ºC 45“ 35x 
C13M63 55°C 68ºC 10’ 
C14M17 55°C   
B5M124 55°C   
B5M5 55°C 
 
2.2.2.3. Nested PCR Detection of K76T PfCRT 
 
Lysine substitution to threonine in PfCRT amino acid 76 is a common feature found 
in most chloroquine resistant (CQR) parasites. In the progeny of Dd2xHB3 cross, the 
substitution is inherited from the CQR parent, Dd2, whereas those progeny inheriting 
the pfcrt gene from the chloroquine sensitive (CQS) parent, HB3, retains the wild-
type K76. Therefore, whenever the length polymorphisms not sufficient for strains 
validation nested PCR detection of K76T PfCRT was employed to identify the strains 
(Djimde et al., 2001).  
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2.2.2.3.1. Nested PCR 
 
The first pair of primers used in the reaction consists of the flanking primers CRTP1 
and CRTP2, which amplify a 537 base pair region around the mutation K76T. The 
second reaction was performed with the internal primers flanking the K76T mutation, 
CRTD1 and CRTD2, producing a 145 base pair amplicon (Djimde et al., 2001). The 
first reaction was performed for ten cycles, then the thermocycler was stopped and 
0.5 µl PCR products was taken and transferred to second PCR mixture. The 
thermocycler was restarted and run for 35 cycles. 
 
Nested PCR of K76T PfCRT 
First PCR Mixture (25 µl)  Second PCR Mixture (25 µl) 
Euro-Taq buffer (10x)        2.5 µl  Euro-Taq buffer (10x)        2.5 µl 
dNTPs (10 mM)                0.5 µl  dNTPs (10 mM)                0.5 µl 
CRTP1 primer (50 µM)      0.5 µl  CRTD1 primer (50 µM)      0.5 µl 
CRTP2 primer (50 µM)      0.5 µl  CRTD2 primer (50 µM)      0.5 µl 
MgCl2 (50 mM)   1.25 µl  MgCl2 (50 mM) 1.25 µl 
Template gDNA   1 µl  First PCR Amplicon   0.5 µl 
DNA-Polymerase (1u/ µl)   0.25 µl  DNA-Polymerase (1u/ µl)   0.25  µl 
H2O     18.5 µl  H2O     19 µl 
 
PCR Reactions 
First PCR Reaction  Second PCR Reaction 
94ºC 4’   95ºC 45“  
94ºC 45“   59°C 45“  
59°C 45“   68ºC 1’ 35x 
68ºC 1’ 10x  68ºC 10’  
Thermocycler was stopped and 0.5 µl amplicon was 
transferred to the second PCR mixture 
   
 
2.2.2.3.2. Restriction Digests 
 
The nested PCR amplicon was digested with restriction enzyme ApoI. The enzyme 
digests only the sensitive type allele, resulting in a size reduction of 34 base pairs, 
but does not digest the resistant allele (Djimde et al., 2001). The digest product was 
run on 2% agarose gel at 120 V for at least 30 minute before checking. 
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Digest Reaction   
The second PCR amplicon  8 µl
NEB Buffer 3  1 µl
BSA (10x)  1 µl
ApoI Enzyme  0.5 µl
Incubation at 50ºC for 6 hours   
 
2.2.2.4. Agarose Gel Electrophoreses 
 
In this project analytical agarose gel electrophoresis was employed to for size 
determination of PCR fragments. Two types of gels were used, the 2 or 3% normal 
agarose and 2% Metaphor® gel electrophoreses. MetaPhor® is an analytical special 
agarose with intermediate melting temperature 75ºC with twice the resolution 
capabilities of the finest-sieving agarose product (Cambrex Bio Science Rockland, 
2003). In this project, 2% Metaphor® agarose in TAE buffer was used to distinguish 
PCR products with very small size differences during strains validation. To make the 
electrophoresis gel, an appropriate quantity of agarose was added to TAE and the 
mixture was boiled until the agarose was completely dissolved. Ethidium bromide 
was added to a final concentration of 1 µg/ml. Ethidium bromide intercalates with the 
DNA allowing visualization by UV irradiation. DNA samples were mixed with loading 
buffer (1:5, v/v) and loaded on the gel. As a size marker, the 1 Kb Plus DNA 
Ladder™ was used. Electrophoresis was performed at a constant voltage of 120 V in 
TAE. The result was photographed using a DC120 Zoom Digital Camera (Kodak). 
2.2.3. Measurement of Drugs Accumulation 
 
Accumulations of CQ and QN were measured in throphozoites culture with very high 
parasitaemia (approximately 95-97%). To obtain the required concentration and 
parasitaemia, the culture had to undergo several treatments, starting with sorbitol 
synchronisation approximately 16-18 hours prior to experiment and followed by 
MACS column purification before the cells were eventually diluted to the right 
concentration. The amount of drug presents in the cell and medium was obtained by 
measuring the radioactivity of the labelled drugs used in the experiment. The method 
was already previously fully described (Sanchez et al., 2003, Sanchez et al., 2008b). 
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2.2.3.1. Preparation of Culture 
 
MACS purified trophozoite-infected RBC was reconstituted in prewarmed RPMI 1640 
(pH7.4 at 37°C) to a cell concentration of 25000-32000 cells/µl. The exact 
concentration was determined using a Thoma counting chamber. The parasite’s 
trophozoite stage was confirmed with light microsopic examination of Giemsa-stained 
blood smears.  
2.2.3.2. Accumulation Experiment 
 
In the parental strains (Dd2 and HB3) QN accumulation was measured at full time 
course, that is, accumulation was measured periodically starting from 30 seconds 
after the drug was added until the accumulation reached stationary phase. In the 
progeny, a time point corresponding to the drug initial uptake state and another one 
corresponding to the steady state were selected and drug accumulation at these time 
points only were measured. 
 
 
Figure 2.3. Accumulation Experiment 
(A) 75 µl duplicated aliquot of radioactive culture were each placed in a prepared tube 
containing oil solution and cold RPMI medium. The tubes were then centrifuged (15000 g, 1 
min) to separate the cells from the aqueous medium (B) After centrifugation cells were 
separated from the aqueous medium. The pelleted cells were isolated by cutting the tip of the 
tube. 
 
Trophozoite culture (25000-32000 cells/µl, 95-97% parasitemia) in RPMI 1640 
(pH7.4 at 37°C) was pre-incubated for 2 min at 37°C. [3H]-drug was added to the pre-
incubated culture to a concentration of 40 nM, and then the treated culture was 
75 µl aqueous medium was 
then taken and radioactivity 
was measured  
oil solution 
aqueous medium 
After Centrifugation 
peletted cells 
100 µl oil 
solution 
75 µl RPMI pH 7.4 
at 4ºC 
75 µl radioactive 
culture 
Taking aliquoted sample 
of treated culture 
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mixed and incubated in a waterbath set at 37ºC. 75 µl aliquot of the radioactive 
treated-culture was taken in duplicate at each corresponding time point after the 
addition of the drug. Each aliquot was diluted with equal volume of ice-cold RPMI 
1640 (pH7.3 at 4°C). The ice-cold medium should stop any active transport of the 
drug. These aliquot-cold medium mixtures were immediately spun through a layer of 
oil solution containing 5:4 mixture of dibutyl phthalate and dioctyl phthalate (15000 g, 
1 min) to separate the cells from the aqueous medium containing the unincorporated 
labelled drug, hence preventing further entry of the drug to the cells. 
2.2.3.3. Estimation of Drug Level by Radioactivity 
Measurement 
 
The cell pellets that had been separated from the medium was placed in a 1.5 ml 
Eppendorf tube and incubated with 66 µl of ethanol and 33 µl of tissue solubiliser 
overnight at 55°C. The lysate was then decolorised by the addition of 25 µl of 30% 
H2O2 and acidified by the addition of 25 mL of 1 N HCl. The lysate was transferred to 
a scintillation vial, and the radioactivity was measured. The amount of radioactivity in 
the known volume of aqueous medium was also measured. The intracellular drug 
concentration was calculated from the amount of labelled drug taken up by the cells 
and by assuming that the volume of a trophozoite-infected erythrocyte is 75 fL 
(Saliba et al., 1998). Drug accumulation was then expressed as the ratio of the 
intracellular to the extracellular drug concentration (drugin/drugout) (Sanchez et al., 
2008b). 
2.2.4. QTL Analysis 
 
In this project, the QTL analysis was performed using an Excel sheet calculation 
designed by Prof. W. Stein from the Department of Biological Chemistry, Hebrew 
University of Jerussalem, Israel. The calculation was performed based on the simple 
regression method QTL analysis as described by Haley and Knott (Haley & Knott, 
1992). A table provided as an Excel file at NCBI (National Center for Biotechnology 
Information) website (National Center for Biotechnology Information, 2000) provides 
a full listing of the parental (Dd2 or HB3) origin of each of the 900 microsatellite 
markers mapped by Su et al. (Su et al., 1999), with their location in cMs along each 
chromosome.  
Of these 900 microsatellite markers, only 818 of these markers were used on this 
project, removing 82 markers where the information was incomplete. The markers 
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were arranged as rows in the table. For each of the 36 strains, arranged in columns, 
the appropriate drug accumulation value was inserted. For the comparable analysis 
of the IC90 values, the QN IC90 values were taken from the publication of Ferdig et al. 
(Ferdig et al., 2004). If, from the NCBI data, a marker for a particular strain was 
derived from the Dd2 strain, a 1 was entered into the table at the appropriate 
intersection, whereas if the origin was from the HB3 strain, a 0 was entered. This 
then gave a matrix of 818 x 36 numbers in 0 and 1. For each marker (each row), a 
Pearson regression of the 0’s and 1’s were performed against the measured 
accumulation or the IC90, to yield the Pearson r for the marker. (The Pearson r for a 
marker is a measure of how well the pattern of 0 and 1 values across the strains, for 
that marker, predicted the measured values of accumulation or IC90). The probability 
p was determined with the appropriate degrees of freedom. For the entire 818 
markers, the p value was divided by the mean of p values. This ratio showed whether 
the p value was higher or lower than the mean. The logarithm of this ratio gave the 
LOD (logarithm of odd) score. Therefore, when a marker had a negative LOD score, 
its p value was lower than the mean, and vice versa. A p value of 100 times less than 
the mean (p<0.01) was taken as being the significance limit and a line at this level 
was drawn in all the LOD score figures, hence the peak positions of LOD scores, 
chromosome by chromosome, were readily determined. 
The sign of the regression coefficients used to derive the LOD scores indicated 
whether or not an increase or a decrease in a measured quantity was being reported. 
When a marker had a negative Pearson r value, it had decreasing effect to the 
measured quantity, and vice versa. 
The QTL primary scan was performed by regression analysis across all 36 strains, 
thus aiming to find factors affecting major variations between the strains. The QTL 
secondary scans were performed by regression analysis within either the 17 strains 
inheriting pfcrt locus from Dd2 (CQR strains) or the 19 strains inheriting the locus 
from HB3 (CQS strains), taking the appropriate degrees of freedom. The secondary 
scan should have pointed at factors affecting phenotypic variations within the groups. 
2.2.5. Mathematical Analysis of Loci Interactions 
 
The mean of QN accumulation and IC90 levels of strains were calculated at different 
combinations of loci. P values were calculated to determine whether there were 
significant differences between the means. Strains were analysed whether the 
significance in the difference of means is correlated to allelic difference in the 
analysed loci.  
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2.2.6. Bioinformatics Analysis 
 
Bioinformatics analysis was performed on the chromosomal areas under the peaks to 
find candidate genes. After determining the peaks positions by QTL analysis, 
molecular markers located under peaks were identified by comparing the NCBI 
microsattelites marker map  with the Sequence Tagged Site (STS) and gene maps 
as published in NCBI gene bank . Then, genes located within and directly adjacent to 
these markers were identified and selected using online databases PlasmoDB 
(PlasmoDB, 2008a) and NCBI gene bank (National Center for Biotechnology 
Information, 2008). 
The selected genes were analysed further for their putative functions, the presence 
of polymorphisms in the parental strains, and the presence of transmembrane 
domains (TMD). 
Some of the genes had their putative functions already annotated in PlasmoDB and 
NCBI gene bank. Whenever the functions of the genes were not accessible from 
PlasmoDB or NCBI gene bank, Basic BLAST (Basic Local Alignment Search Tool) 
search hosted by the Swiss Institute for Bioinformatics (EMBNet, 2008) was 
performed to predict the putative functions of the gene products by comparing the 
sequence to find similarity with other genes in the database.  
Since the annotated genes in PlasmoDB and NCBI were all based on 3D7 genomic 
sequence, the selected genes had to be further analysed for the presence of 
polymorphisms between Dd2 and HB3 by BLAST search on Dd2 and HB3 sequence 
databases in Broad Institute MIT (BROAD, 2009). 
Polymorphisms within transporters have long been associated with altered quinoline 
drug sensitivity (Sanchez et al., 2008, Sidhu et al., 2002, Fidock et al., 2000, 
Lakshmanan et al., 2005). Therefore, finding transporters is one of the targets in this 
analysis. For this purpose, analysis was performed to look for genes expressing 
protein with TMD, as the presence of TMD is a prerequisite of a membrane 
transporter (Busch & Saier, 2002). The prediction of TMD was performed based on 
hidden Markov model (Krogh et al., 2001), using TMHMM (Transmembrane domain 
Hidden Markov Model) Server (CBS, 2007). The number of TMDs were double 
checked by comparing it to the annotated data in PlasmoDB, which were also 
determined the Hidden Markov Model (HMM) using a different software called 
HMMPfam (PlasmoDB, 2008b).  
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3. Results 
3.1. Validation of Strains Used in the 
Accumulation Experiments 
 
From the 35 progeny of the  Dd2xHB3 cross performed by Wellems (Wellems et al., 
1990), 34 were used in this project. One of them, the C101, was not available from the 
MR4 during the time of the project, and therefore had to be excluded. Prior to being 
used for the accumulation experiment, these strains, the progeny as well as the 
parents, had to be genetically checked to validate. The validation was performed by 
comparing the fragment length polymorphisms of certain microsatellites and K76T 
mutation (Djimde et al., 2001) patterns in these strains with the known segregation 
patterns as published at the NCBI home page (National Center for Biotechnology 
Information, 2000). The microsatellites and pfcrt segregation patterns can be seen in 
Table 3.1. 
For the microsatellite fragment length polymorphisms, a selection of microsatellites 
and their primer sequences were kindly provided by Dr. J. Mu of the NIH, whereas the 
K76T mutation was detected by nested PCR as described previously by Djimde et al. 
(Djimde et al., 2001). All strains used in this project had been tested and proven that 
the genetic components met the segregation pattern as described in Table 3.1., prior 
to being used in the drug accumulation experiments. 
       
Table 3.1. Strains used in the project and their patterns of microsatellite polymorphisms and pfcrt inheritance 
H: originated from HB3, D: originated from Dd2, CQR: Chloroquine Resistant, CQS: Chloroquine Sensitive, R: Resistant, S: Sensitive 
              Parental strains 
              Progeny 
 
 
 
Markers Dd2 HB3 B1SD QC13 QC01 B4R3 SC05 TC08 GC03 3BA6 1BB5 3BD5 SC01 QC34 QC23 TC05 GC06 D43 C188 
C1M4 D H D D D H H H D H D D H D D H D D H 
C1M67 D H H H D H D H D D D D D H H H D H H 
C4M62 D H D D H H H H D H D D D D H D D D D 
C13M13 D H D H D H D H H D H H H D D D D D D 
C13M63 D H D H D H H H H D H H H D D D D D D 
C14M17 D H H H D D H H D H D H D H D H D H H 
B5M124 D H D D D H H H H D H H H H D H H H D 
B5M5 D H D D H H H D D H D H D H H D D H H 
pfcrt origin D H H H H H H H H D D D D D D D D D H 
CQR/CQS R S S S S S S S S R R R R R R R R R S 
Markers C408 CH3-116 CH3-61 7C3 7C7 7C12 7C16 7C20 7C46 7C111 7C126 7C140 7C159 7C170 7C183 7C421 7C424
C1M4 H D H D D H D D D D D H D H D D H 
C1M67 D H D D H D H H H D H H D H H H H 
C4M62 D D D H H D H H D D H D D H H H D 
C13M13 D D D D D D H H H H H D D D H H H 
C13M63 D D D D D D H H H H H H D D D H H 
C14M17 H D D H D D H D D H H D D D D D H 
B5M124 H D H D H D H H H D D D D H D H D 
B5M5 D D D H H D D H H D D H D H H H D 
pfcrt origin D H H H H D H H D D H H H H D D D 
CQR/CQS R S S S S R S S R R S S S S R R R 
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3.2. Quinine Accumulation 
3.2.1. Determination of Initial Steady State Time 
Point from the Full Time Course Quinine 
Accumulation of Dd2 and HB3 
 
At the beginning of the project, QN accumulation was measured periodically in Dd2 
and HB3 to understand the pattern of full time course QN accumulation (Figure 3.1.). 
To ensure robustness of the assay at least five independent measurements were 
carried out for each time point, therefore each time point in this graph represents the 
mean of these measurements, and the error bar represents the standard error 
calculated from these multiple measurements. From this full time course graph, two 
time points were selected, one at the initial uptake state (at 5 min) and the other 
during the steady state (at 20 min). In the progeny, QN accumulation was only 
measured at these two time points, excluding other time points measured in the full 
time course.  
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Figure 3.1. Full time course accumulation of quinine in Dd2 and HB3 
(     HB3;     Dd2) Based on this full time course graph, a time point during the initial uptake 
stage was selected (5 min). QN accumulation in the progeny was measured only at this 
particular time point. 
 
3.2.2. Quinine Initial Accumulation of Dd2, HB3 
and their Progeny 
 
The QN accumulation levels of Dd2, HB3 and the 34 progeny are represented in 
Figure 3.2. As in the parental strains, the accumulation levels in the progeny were 
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also determined from the mean of at least five measurements and each error bar 
represents the standard error of these measurements. 
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Figure 3.2. Quinine initial and steady state accumulation level of Dd2, HB3 and 
their progeny 
QN accumulation levels (A) at 5 min and (B) at 20 min after treatment of the culture with 
radioactive QN. (        strains with pfcrt from HB3;        strains with pfcrt from Dd2). 
 
Although [3H]-Quinine accumulation was measured at two different time points, only 
accumulation during the initial state was used later for QTL analysis. As indicated in 
the graph (Figure 3.2.), the measurements at the two different time points showed 
very similar patterns. The only difference between the two sets of data was the error 
bars, which were smaller in the early steady state, indicating that at initial state the 
measurements gave more consistent results than at the early steady state. This 
A 
B 
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might have been caused by saturation of the drug to the transport machinery of the 
parasites instead of reduction of cell viability, since Trypan Blue treatment and 
visualisation under light microscope showed no difference in the cells viability after 5 
and 20 minutes treatment with QN (data not shown). 
Figure 3.2. showed that the CQR parental strain (Dd2) accumulated a low amount of 
QN, whereas the CQS parental strain (HB3) accumulated higher amount of QN. 
Amongst the progeny, however, there are variations in the accumulation levels. 
Some progeny accumulated as much QN as the resistant parent (Dd2), whereas 
others accumulated QN to the level comparable to that of HB3. In addition to these 
two phenotypes, there are also progeny accumulating intermediate level of QN, such 
as TC05 and CH3-116, and those accumulating even higher level than the sensitive 
strains, such as B1SD and C188. This phenotypic pattern implies that more than one 
factor might be involved in QN accumulation. 
3.2.3. Multifactorial Inheritance of Quinine 
Accumulation as Indicated by the Accumulation 
Pattern 
 
The 17 columns on the left side of both parts of Figure 3.2. depicted QN 
accumulation in the strains having mutated pfcrt gene and showing CQR character, 
while the remaining 19 columns (on the right of each sub-figure) were data from the 
strains having wild-type pfcrt and showing sensitivity to CQ. Variation between 
strains having the same pfcrt gene further suggests that pfcrt is not a single factor 
affecting QN accumulation. 
During this project, parallel to measuring the QN accumulation, CQ accumulation 
was also measured (in collaboration with Sybille Mayer) at early uptake state (4 min) 
in all strains (Mayer, 2009). This was intended to be a control, since it had been 
shown by QTL analysis that pfcrt was the single major determinant of CQ resistant 
(Ferdig et al., 2004, Bray et al., 2005) and that the CQR strains having mutated pfcrt 
accumulated less CQ than the CQS strains with wild-type pfcrt (Cooper et al., 2007, 
Sidhu et al., 2002). This pattern, where CQR strains with mutated pfcrt accumulated 
less CQ than CQS strains with wild-type pfcrt was also observed (Mayer, 2009), 
hence proving the validity of the method used. 
The continuous variation as shown by the QN accumulation level (Figure 3.2.) was 
typical of the multifactorial phenotype, and in contrast to  the classical single gene 
Mendelian inheritance, with typical bimodal distribution in the population (Sen & 
Ferdig, 2004). The results indicated that there was no clear distinction between 
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strains having wild-type (QN accumulation = 182.6 ± 5.2 units) or mutant pfcrt (QN 
accumulation = 130.8 ± 5.7 units), suggesting that QN accumulation is a quantitative 
trait. The means for QN accumulation for the two groups were, however, still highly 
significantly different at p<0.0001. Thus, pfcrt, though not a single determinant, is a 
major factor affecting QN accumulation. 
3.3. QTL Analysis 
3.3.1. QTL Analysis of Quinine Accumulation 
 
Using quantitative trait loci (QTL) analysis based on IC90 data, Ferdig et al. 
demonstrated that pfcrt is a common determinant in QN and CQ resistance (Ferdig et 
al., 2004), in addition to other factors involved in QN resistance present in 
chromosomes 6, 9 and 13 (Ferdig et al., 2004).  
Although IC50 and IC90 assays have been widely used to study drug response in 
Plasmodium, these assays are indicators for cell viability and cell death after 72 
hours exposure to the drug and, therefore, several factors might influence them, 
including affinity of the drug to its target and intracellular drug concentration, which 
may be affected by the carrier systems. On the contrary, the assay used in this 
project measured the drug accumulation in the parasite within minutes of exposure to 
the drug, which was likely to be determined only by the transport mechanisms. Thus, 
genetic factors found to be linked to the QN accumulation phenotypes by the QTL 
analysis were likely to affect or be involved in the QN transport mechanisms. 
QTL analysis was also performed on CQ accumulation data (Mayer, 2009) as a 
mean of proving the validity of the method, since the CQ system was the one most 
thoroughly studied. 
3.3.1.1. Primary Scan 
 
The QTL primary scan was performed by regression analysis of QN accumulation 
across all 36 strains and aimed to find major factors affecting QN accumulation. 
Figure 3.3. shows the LOD score of QTL analysis primary scan on QN accumulation. 
The horizontal dotted line in this (and all subsequent figures) defines the confidence 
level of p<0.01 (see Methods), so that all peaks arising above this line can be 
considered as well-supported by the data. It should also be noted that a peak in the 
QTL analysis corresponded in general to one or more chromosome markers. This 
number might vary from 1 to 11 in the various peaks, since several markers might 
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share the same position in centiMorgan (cM). Where there were more than one 
marker within a peak, the name of the marker located in the middle of the peak, as 
provided in the NCBI list of markers (see Method), was assigned as the name of the 
peak. The regression data on these peaks were listed in Table 3.2., 3.3. and 3.4., 
where in each case a central chromosome marker present in that peak, was 
recorded. 
In the primary scan, a major double peak was readily seen in chromosome 7. One of 
the major peaks, positioned at pfcrt. The presence of pfcrt as a major peak here was 
not surprising since the gene has often been associated with QN resistance (Ferdig 
et al., 2004) and accumulation (Sanchez et al., 2008b). The peak on the left, 
assigned to the marker B5M12, however, is novel. The Pearson regression showed 
that both peaks had negative correlation to QN accumulation (Table 3.2.), meaning 
that they both work in synergy in reducing the QN accumulation level.  
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Figure 3.3. QTL analysis primary scan of quinine accumulation 
A double peak is observed in the primary scan, one located on pfcrt, whereas the other one is 
novel and assigned to the marker B5M12 (           QN Accumulation;          significant 
threshold p<0.01) 
 
3.3.1.2. Secondary Scan 
 
The QTL secondary scan was performed separately on the 17 mutant pfcrt-
containing strains and the 19 wild-type pfcrt-containing strains. Figure 3.4. (A) 
depicts the QTL analysis across the chromosomes of only the 17 mutant pfcrt-
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containing strains, whilst Figure 3.4.(B) shows the QTL analysis across the 
chromosomes of only the 19 wild-type pfcrt-containing strains.  
Some markers in chromosome 7 were excluded from the secondary scans. These 
markers are located around and segregated with pfcrt. Thus within CQR or CQS 
group, there is no variation of the parental origin of these markers, that is, all CQR 
strains and all CQS strains have inherited the markers from Dd2 and HB3, 
respectively. Therefore, by excluding these markers from the analysis, the major 
effect of pfcrt was removed. In the graph, the excluded markers are represented as a 
gap in chromosome 7. 
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Figure 3.4. QTL analysis secondary scan of quinine accumulation 
(A) LOD score of secondary scan on 17 CQR strains (B) LOD score of secondary scan on 19 
CQS strains (           QN Accumulation;            significant threshold p<0.01) 
 
3.3.1.2.1. Secondary Scan on CQR Strains 
 
The secondary scan on CQR strains showed significant peaks in chromosome 5, 7, 
11, and 13 (Figure 3.4. (A)). 
The peak in chromosome 5 resides on the marker B5M86, which Ferdig et al. also 
found in his QTL analysis secondary scan on QN IC90 (Ferdig et al., 2004). Only 4.3 
cM away from the B5M86 marker, lies the MDR1 marker containing pfmdr1 gene. 
Although not at the top of the peak, the MDR1 marker is located within the B5M86 
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peak. B5M86 appeared only in the secondary scan, but not in the primary scan. The 
Pearson regression showed that B5M86 peak had a positive correlation to QN 
accumulation, meaning that the peak contributes positively to QN accumulation. 
In chromosome 7, the B5M12 peak appeared again. The peak had a negative 
correlation to QN accumulation. However, this peak was not present in the secondary 
scan on CQS strains (Figure 3.4. (B)). 
The peak in chromosome 11 is located on marker B7M99 at 83.3 cM, whereas in 
chromosome 13, there was a peak found on MEF_1 marker, located at 32.6 cM. 
However, this peak nowhere near the pfnhe gene, which is often associated with QN 
resistance (Bennett et al., 2007). The pfnhe gene is positioned in the vicinity of the 
TA46 marker (at 173.1 cM). 
3.3.1.2.2. Secondary Scan on CQS Strains 
 
Only one peak was observed in the QTL secondary scan on CQS strains, that is the 
C5M2 peak located in chromosome 5. Pearson regression showed that the peak 
contributed positively to QN accumulation (Figure 3.4. (B)). 
3.3.2. QTL Reanalysis of Ferdig’s Quinine IC90 Data 
with and without Verapamil 
 
In their publication, Ferdig et al. (Ferdig et al., 2004) published QTL analysis data of 
CQ and QN IC90, and QN IC90 in the presence of verapamil (QN-VP IC90). Verapamil 
is an L-type calcium channel blocker known to be able to reverse CQ resistance 
(Martin et al., 1987, Martiney et al., 1995). In this project, Ferdig’s data of QN IC90 
and QN-VP IC90 were reanalysed.  
There were two major double peaks, located in chromosome 7 and 13, observed in 
the primary scan of QN IC90. Although the LOD score is not as high as in QN 
accumulation QTL analysis, the dominant peak in chromosome 7 again correlated to 
pfcrt. In agreement with its negative contribution to accumulation, the regression 
coefficient showed that pfcrt had a positive correlation to IC90. Plotting the QN IC90 
and QN-VP IC90 data sets in the same graph showed that this pfcrt peak was 
verapamil-sensitive (Figure 3.5. (B)). 
The B5M12 peak, which appeared pronouncedly as the left peak of chromosome 7 in 
the QN accumulation QTL analysis, was not readily visible in QN IC90. Despite its 
significant LOD score, B5M12 appeared only as a small protrusion to the left of the 
pfcrt peak in the QTL analysis of QN IC90. The presence of B5M12 in the primary 
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scans of both QN accumulation and IC90 can be seen in Figure 3.5. (B). B5M12 peak 
is also VP sensitive. 
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Figure 3.5. Comparing the QTL analysis primary scan of QN accumulation with 
the QTL reanalysis of Ferdig’s QN IC90 and QN-VP IC90 
(A) Scan across all 14 chromosomes (B) Peaks in chromosomes 7, 5 and 13 
(           QN Accumulation;            QN IC90;            QN-VP IC90;           significant threshold 
p<0.01) 
 
In the QTL analysis of QN IC90data, there were two clearly separated peaks in 
chromosome 13, which were only small or even absent in the QN accumulation data 
set. The left peak, VAPA, is located at 3.27 cM, whereas the right peak, C13M73, is 
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located at 178.8 cM. C13M73 is exactly at the same position in cM as the C13M56 
peak published by Ferdig’s group. Despite their hypothesis that pfnhe might be 
present within the peak they found in chromosome 13 (Ferdig et al., 2004) and a 
more recent publication suggesting involvement of PfNHE in QN resistance (Bennett 
et al., 2007, Nkrumah et al., 2009), the reanalysis of Ferdig’s IC90 data showed that 
pfnhe was not located in either of the two peaks in chromosome 13. Instead, the 
gene, which was positioned within TA46 marker, was located in the valley between 
the two peaks.  
The regression coefficient showed that both VAPA and C13M73 peaks in 
chromosome 13 had positive contribution to IC90, hence reducing sensitivity to QN. 
Superimposing the QTL analysis data of QN IC90 with and without verapamil showed 
that the presence of verapamil affected the C13M73 peak only slightly whilst 
completely diminishing the VAPA peak. A peak, TA58, lying within the shoulder of the 
C13M73 peak, was found in QN-VP IC90 data. The presence of TA58 peak further 
proved that C13M73 peak was not greatly affected by the presence of verapamil. 
 
Table 3.2. List of QTL primary scan peaks 
 peak with negative correlation  peak with positive correlation 
 not a peak, negative correlation  not a peak, positive correlation 
 
LOD Scores Chr. Marker  
Name 
Marker  
Number 
Position 
[cM] QN Acc. QN IC90 QN-VP IC90 
5 B5M132 214 57.3 -0.23 0.62 3.10 
7  B5M12 297 5.8 6.25 2.00 1.30 
7 PfCRT  310 20.2 7.00 2.82 1.29 
11 TA31 507 43.1 0.15 2.05 0.97 
13 VAPA 705 164.5 0.71 3.27 0.37 
13 C13M73 717 178.8 -0.01 3.51 2.44 
13 TA58 719 184.5 -0.23 2.81 2.80 
 
In the primary scan of the QN-VP IC90 there was a quite pronounced peak (B5M132) 
on chromosome 5, which was not apparent when verapamil is absent. The 
regression coefficients show that the B5M132 peak contributed negatively to IC90, 
hence increasing sensitivity. Verapamil is known to have intrinsic antiplasmodial 
activity independent to its capability in reversing CQR (Adovelande et al., 1998). It 
was also reported previously that mutations in pfmdr1 modulated P. falciparum 
sensitivity to the intrinsic antiplasmodial activity of verapamil (Hayward et al., 2005). 
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Therefore, it is interesting to see that this peak, B5M132, is located in chromosome 
5, around 8.6 cM away from pfmdr1. 
3.3.2.1. Secondary Scan 
 
In the secondary scan of QN IC90 and QN-VP IC90 reanalysis several peaks were 
found and listed in Tables 3.3. and 3.4. As mentioned previously, the secondary 
scans aim to find factors affecting variations within the CQR or CQS strains, since 
the scans were performed on either the wild-type or mutant pfcrt carrying strains. 
As with the secondary scan of QN accumulation, pfcrt and markers located close to 
and segregated with pfcrt were also excluded from the secondary scans performed 
on QN IC90 and QN-VP IC90 data to remove the effects of pfcrt. The excluded 
markers were represented as gaps in chromosome 7 (Figure 3.6. (A) and (B)). 
3.3.2.1.1. Secondary Scan on CQR Strains 
 
For the first time, the analysis showed MDR1, the marker where pfmdr1 resides, as a 
significant, verapamil sensitive peak located in chromosome 5 in the secondary scan 
on CQR strains of QN IC90. The regression coefficient showed that the peak 
contributed negatively to QN IC90.  
 
Table 3.3. QTL secondary scan on CQR strains peaks 
 peak with negative correlation  peak with positive correlation 
 not a peak, negative correlation  not a peak, positive correlation 
 
LOD Scores Chromosome  
Number 
Marker  
Name 
Marker  
Number 
Position 
[cM] QN Accumulation QN IC90 QN-VP IC90 
2 BM41 60 57.5 -0.31 0.57 2.37
5 B5M86 217 60.2 2.10 1.79 0.52
5 MDR1 222 65.9 1.80 2.28 0.77
6  BM75 266 31.7 0.80 2.43 0.64
6 BM103 289 100.5 0.73 2.00 -0.03
7  B5M12 297 5.8 2.98 0.33 -0.16
11 B7M99 521 83.3 2.13 -0.20 -0.29
12 Y588M4 557 71.6 0.02 1.18 2.50
12 Y812M3 565 88.8 0.02 1.18 2.50
13 MEF_1 632 32.6 3.65 0.90 0.16
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As mentioned previously, MDR1 is located close to B5M86, a peak which appeared 
in the secondary scan of QN accumulation data. Again, as in the secondary scan of 
QN accumulation data, scanning the QN IC90 data showed that both markers were 
located within the same peak (Table 3.3. and Figure 3.6. (B)). It is very probable, 
therefore, that the effect shown by these markers corresponded to the same locus or 
gene. 
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Figure 3.6. Comparing the QTL analysis secondary scans on CQR strains of 
QN accumulation and QTL reanalysis of Ferdig’s QN IC90 
(A) Scan across all 14 chromosomes (B) Peaks in chromosomes 5, 6 and 7  
(           QN Accumulation;            QN IC90;            QN-VP IC90;           significant threshold 
p<0.01) 
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In chromosome 6, a peak located on the marker BM75 appeared in QC IC90. The 
regression coefficient shows that BM75 contributes positively to QN IC90 but does not 
seem to affect QN accumulation. This peak is also abolished by the presence of 
verapamil.  
BM75 is located at the same cM position as a peak called B5M74 mentioned in the 
work of Ferdig and colleagues (Ferdig et al., 2004). The paper mentioned that 
B5M74 interacted with pfcrt and B5M74 originated from Dd2 increased the positive 
effect of pfcrt to IC90. It seems that both BM75 and B5M74 corresponded to the same 
gene located in that area. 
3.3.2.1.2. Secondary Scan on CQS Strains 
 
Several peaks appeared in the secondary scan of QN IC90 data on CQS strains. The 
largest peak was the VP-resistant C13M73, which is located in chromosome 13. This 
peak was also present in the QN IC90 primary scan but not present in the secondary 
scan on CQR strains, suggesting that the peak found in the primary scan were solely 
contributed by the CQS strains (Figure 3.7. (B)). 
The C5M2 peak, which appeared significantly in the secondary scan of QN 
accumulation, was not present at all in QN IC90 (Figure 3.7. (B)). 
Unlike in the secondary scans on CQR strains, in this secondary scan on CQS 
strains MDR1 and B5M86 peaks were no longer significant (Figure 3.7. (B)). 
Another peak, readily seen in the secondary scan on CQS strains was B5M4, located 
in chromosome 6. The presence of this peak was not affected by VP. 
 
Table 3.4. QTL secondary scan on CQS strains peaks 
 peak with negative correlation  peak with positive correlation 
 not a peak, negative correlation  Not a peak, positive correlation 
 
LOD Scores Chromosome  
Number 
Marker  
Name 
Marker  
Number 
Position 
[cM] QN Acc. QN IC90 QN-VP IC90 
5 C5M2 194 20 2.58 0.29 0.14 
6 B5M4 263 23.1 -0.27 2.02 2.29 
13 C13M73 717 178.8 -0.18 3.14 3.68 
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Figure 3.7. Comparing the QTL analysis secondary scans on CQS strains of QN 
accumulation and QTL reanalysis of Ferdig’s QN IC90 
(A) Scan across all 14 chromosomes (B) Peaks in chromosomes 5, 6 and 13 (      QN 
accumulation;            QN IC90;           QN-VP IC90;           significant threshold p<0.01) 
 
3.4. Mathematical Analysis of Selected 
Peaks 
 
Mathematical analyses were performed to an assorted number of positive loci to 
determine the effects of these loci to the phenotype, i.e. the QN accumulation or IC90, 
and whether some of these loci interact with one another. 
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3.4.1. Only Dd2 Version of B5M12 Present in CQR 
Strains Affects the QN Accumulation and IC90 
 
The observation of B5M12 peak was novel. The peak was not observed by Ferdig in 
his QTL analysis of QN IC90 (Ferdig et al., 2004) (See Appendix 1 (A)). This might 
have been caused by lower LOD score that they obtained, affecting the resolution of 
the peak. Nevertheless, in the reanalysis of Ferdig’s data performed in this project, a 
small, not so obvious protrusion correlated to B5M12 appeared to the left of the pfcrt 
peak in the primary scan. This peak had positive contribution to IC90. 
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Figure 3.8. The effects of B5M12 and pfcrt origins to quinine accumulation and 
IC90 
The means of (A) QN accumulation and (B) QN IC90 levels when different B5M12 alleles 
coming from Dd2 and HB3 were tested to see whether the origins of B5M12 and pfcrt 
significantly affect the levels. The results showed that Dd2 allele of B5M12 significantly 
affected both QN accumulation and IC90 only when pfcrt was also inherited from Dd2, i.e. in 
CQR strains. (    B5M12 from Dd2;     B5M12 from HB3) 
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In addition to its manifestation in the primary scan of QN accumulation, the B5M12 
peak also appeared in the secondary scan on strains having mutated pfcrt, but not in 
the secondary scan on strains having wild-type pfcrt. Thus, suggesting that the 
presence of B5M12 peak in QN accumulation was contributed solely by CQR strains. 
To prove this hypothesis, the effect of B5M12 and pfcrt origins to the levels of QN 
accumulation and IC90 was tested. The mean of QN accumulation and IC90 levels of 
strains having different combinations of loci were calculated. P values were 
calculated to determine whether there was significant difference between the means, 
when both loci came from HB3 or otherwise.  
Bearing in mind that all CQR strains inherited pfcrt from Dd2 and all CQS strains 
have inherited pfcrt from HB3, the results showed that CQS strains with Dd2-like 
B5M12 and CQR strains with Dd2-like pfcrt did not give significantly different levels of 
QN accumulation and IC90 in comparison to CQS strains with B5M12 from HB3. 
However, CQR strains with B5M12 from Dd2 showed significantly different level of 
QN accumulation and IC90 compared to CQS strains with B5M12 from HB3. 
Therefore it seemed that B5M12 had a major effect over QN accumulation and IC90 
only when it came from Dd2 and was present in strains having Dd2-like pfcrt, or in 
other words, in CQR strains. Thus, as clearly depicted in Figures 3.8. (A) right and 
(B) right, the Dd2 alleles of B5M12 and B5M47, which contain pfcrt, act 
synergistically increasing IC90 and reducing accumulation. 
3.4.2. Dd2 Alleles of VAPA and C13M73 are 
Associated with Higher QN IC90 but not Accumulation 
 
C13M73 was one of the major peaks appearing in the primary scan of Ferdig’s QN 
IC90 data reanalysis. This peak is located at the same cM position as C13M56 peak 
discovered by Ferdig (Ferdig et al., 2004), and thus very likely to correspond to the 
same gene. This peak was, however, absent in the QTL analysis of QN 
accumulation. 
In this project, the effects of Dd2 allele at C13M73 locus to QN IC90 and accumulation 
were tested, using pfcrt effect as a background. The result showed that Dd2 allele of 
C13M73 had an additive effect to QN IC90. The value of QN IC90 was significantly 
increased in the presence of Dd2 allele of C13M73, regardless of the origins of pfcrt 
(Figure 3.9. (A) and (B) middle) or B5M12 (Figure 3.9. (A) and (B) lower). Thus, 
indicating that the C13M73 effect is independent of pfcrt and B5M12. There was, 
however, no effect of the C13M73 locus to QN accumulation observed (Figure 3.9. 
(B)). 
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Figure 3.9. The effect of C13M73 to quinine accumulation and IC90 
The means of (A) QN accumulation and (B) QN IC90 levels when different C13M73 alleles 
coming from Dd2 and HB3 were tested to see whether the origins of C13M73 and pfcrt 
significantly affect the levels. The results showed that Dd2 allele of C13M73 was associated 
with higher QN IC90. However, neither HB3 nor Dd2 allele of C13M73 affected QN 
accumulation. Adding BM12 added no influence the effect of C13M73.  
 C13M73 from Dd2   C13M73 from HB3
 
 
The same test was also applied to the VAPA peak, which is the other major peak in 
chromosome 13 appearing only in the primary scan of Ferdig’s QN IC90 data 
reanalysis. Just like the C13M73 peak, VAPA had no effect to QN accumulation 
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(Figure 3.10. (B)). The Dd2 allele of this of this peak again showed an additive effect, 
significantly increasing QN IC90 value (Figure 3.10. (A)), independent of the origins of 
pfcrt and B5M12. 
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Figure 3.10. The effect of VAPA to quinine accumulation and IC90 
The means of (A) QN accumulation and (B) QN IC90 levels when different VAPA alleles 
coming from Dd2 and HB3 were tested to see whether the origins of VAPA and pfcrt 
significantly affect the levels. It was shown in the results that just like C13M73, Dd2 allele of 
VAPA significantly affected QN IC90, but had no effect at all to QN accumulation. 
 VAPA from Dd2   VAPA from HB3
 
                                                                                                                           Results 
 67 
3.4.3. MDR1 and B5M86 Showed the Same Effect 
on Both Quinine Accumulation and IC90 
 
Peaks correlated to MDR1 and B5M86 appeared in the secondary scans only. Since 
these peaks were found only in the secondary scans and not in the primary scans, 
their contribution should not be major. 
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Figure 3.11. The effect of MDR1 and B5M86 to quinine accumulation and IC90 
The means of QN accumulation and QN IC90 levels when different (A) MDR1 and (B) B5M86 
alleles coming from Dd2 and HB3 were tested to see whether the origins of the loci 
significantly affect the levels. The two loci seemed to have exactly the same effects to QN 
IC90. HB3 alleles of both loci were associated with higher QN IC90.  
 from Dd2   from HB3
 
Within the MDR1 marker, resides the pfmdr1 gene. PfMDR1 is often associated with 
increased in vitro QN resistance (Sidhu et al., 2005, Sidhu et al., 2006), although a 
recent publication by Sanchez et al. shows that there was no difference in the level of 
accumulated QN in Xenopus laevis oocytes expressing HB3 and Dd2 types pfmdr1 
(Sanchez et al., 2008).  
The mathematical analysis of QN accumulation showed that MDR1 marker had 
almost no effect to accumulation in CQS strains and only a slight, though significant 
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positive effect to accumulation in CQR strains seemed to be contributed by the Dd2 
allele (Figure 3.11. (A) right). This is consistent with the result of the QTL analysis, 
where the significant MDR1 peak only appeared in the secondary scan on CQR 
strains but not on CQS strain.  
The analysis of Ferdig’s IC90 data showed that the Dd2-type MDR1 was associated 
with decreased QN IC90 regardless of the origin of pfcrt (Figure 3.11. (A) left), 
suggesting that this allele had additive effect to the phenotype. 
As mentioned previously, the secondary scans of both QN accumulation and IC90 on 
CQR strains showed overlapping peaks containing both B5M86 and MDR1 markers, 
although not necessarily as the marker with the highest LOD score (Figure 3.6. and 
Table 3.3.). Since the two markers are located in close proximity to one another and 
showed the same effects to both accumulation and IC90 (Figure 3.11. (A) and (B)), it 
is very likely that the effect of the two peaks corresponded to the same loci or gene. 
In addition, since pfmdr1 is located within these peaks, then the possibility that 
pfmdr1 is the underlying gene responsible for the effect is not unlikely. 
3.4.4. The Inheritance of Dd2 Alleles at both BM75 
and pfcrt Results in Higher Quinine IC90 but Has no 
Effect on Quinine Accumulation 
 
BM75 was a peak found only in the secondary scan on CQR strains of QN IC90 and 
did not appear at all in QN accumulation. The peak was located at the same cM 
position as B5M74, mentioned in Ferdig’s paper as a locus interacting with pfcrt. In 
the paper they mentioned that the inheritance of Dd2 alleles in both pfcrt and B5M74 
had increased substantially QN IC90 value in comparison to other possible allelic 
combinations at these loci (Ferdig et al., 2004). 
As Ferdig’s result showed that B5M74 interact with pfcrt increasing the QN IC90 
value, the BM75 locus increased the QN IC90 level significantly only when there was 
Dd2 allele at the pfcrt locus, indicating that the presence of Dd2 alleles at the two loci 
act synergistically (Figure 3.12. (B)) increasing the IC90 value. Thus, this observation 
supported the previous finding by Ferdig, which mentioned interaction between the 
two loci (Ferdig et al., 2004). 
On the other hand, the analysis on QN accumulation failed to show any significant 
difference in QN accumulation level resulted from different allelic combinations at the 
BM75 and pfcrt loci (Figure 3.12. (A)). 
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Figure 3.12. The effect of BM75 to quinine accumulation and IC90 
The means of QN accumulation (A) and QN IC90 (B) levels when different alleles coming from 
Dd2 and HB3 were tested to see whether the origins of the loci significantly affect the levels. 
Mathematical analysis showed that the the presence of Dd2 alleles at both pfcrt and BM75 
act synergistically increasing the QN IC90 value (B). 
 from Dd2   from HB3
 
3.4.5. HB3-Allele of C5M2 Affects Accumulation in 
Chloroquine Sensitive Strains Only 
 
C5M2 was the only locus appeared in the secondary scan QTL analysis of QN 
accumulation on CQS strains, which did not appear in the QTL analysis of QN 
accumulation on CQR strains nor in the QTL analysis of QN IC90. The locus was also 
not observed in the primary scans of both QN accumulation and IC90. Thus, the QTL 
analysis results suggested that this locus has a minor effect on QN accumulation 
only, and it affects variation within the CQS strains. 
In consistence with the prediction arisen from the QTL analysis results, analysing the 
locus further revealed that the HB3-allele of the locus is associated with lower QN 
accumulation only in strains containing wild type pfcrt, i.e. CQS strains (Figure 3.13. 
(A)), whilst having no effect at all in strains having mutated pfcrt, i.e. CQR strains 
(Figure 3.13. (B)). 
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Figure 3.13. The effect of C5M2 on quinine accumulation and IC90 
The means of QN accumulation (A) and QN IC90 (B) levels when different alleles coming from 
Dd2 and HB3 were tested to see whether the origins of the loci significantly affect the levels. 
Analysis showed C5M2 has no effect to QN IC90 (B) and that HB3-allele of C5M2 is 
associated with lower QN accumulation in CQS strains only (A). 
 from Dd2   from HB3
 
3.5. Bioinformatics Analysis of Positive Loci 
with Major Effects on Quinine Accumulation and 
IC90 
 
Since the target of this project is to find factors affecting QN accumulation and (or) 
resistance, the bioinformatics analysis was performed to find candidate genes 
located within the peaks that might play roles in QN accumulation and (or) 
resistance.  
Two major peaks were selected from the QTL primary scans of QN accumulation and 
IC90. These are the B5M12 peak in chromosome 7, which appeared in QTL analysis 
of QN accumulation, and the VAPA peak in chromosome 13, which appeared in the 
QTL analysis of QN IC90.  
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After identifying molecular markers located under the peaks by comparing the NCBI 
microsattelites marker map  with the Sequence Tagged Site (STS) and gene maps 
as published in the NCBI gene bank , genes located within and directly adjacent to 
these markers were identified and selected by analysis using online databases 
PlasmoDB  and NCBI  gene bank. Several genes could already be excluded early 
during the bioinformatic analysis, since their annotated functions in the NCBI and 
PlasmoDB showed that they were not likely to be involved in accumulation or 
resistance. The examples of these genes were tRNA genes present in B5M12 peak. 
Those with no annotated functions in PlasmoDB or NCBI were analysed further by 
sequence similarity alignment with known gene sequences using Basic BLAST . The 
genes were also analysed for the presence of TMD using TMHMM2 Server  and for 
the presence of polymorphisms between Dd2 and HB3 by BLAST search on Dd2 and 
HB3 sequence databases in Broad Institute MIT . 
3.5.1. Analysis of B5M12 Peak 
 
The B5M12 peak spanned over six markers (four markers lying within area with the 
highest LOD score plus two flanking markers). Within this area 41 genes were 
annotated in PlasmoDB and NCBI gene bank. From these 41 genes, four tRNA 
genes and three genes with no polymorphism between Dd2 and HB3 were excluded, 
leaving 34 genes to analyse. 
Many drug transporters, such as human and bacterial MDR proteins, are members of 
ABC transporter superfamily. ABC transporter might function as dimers or even 
tetramers. Typical ABC transporters contain two intracellular nucleotide binding 
domains (NBDs) and two multiple membrane spanning domains (MSDs) (Kerr, 
2002), each consisting of 6-11 TMDs. 
Transporters that have been associated with drugs resistance in P. falciparum, such 
as PfCRT and PfMDR1, have 10 (Bray et al., 2005) and 11 TMDs (Peel, 2001), 
respectively. PfMDR1 has two homologous halves, each with predicted six TMDs 
(Peel, 2001). Considering that many transporters act as dimers or tetramers, genes 
encoding proteins with at least two predicted TMDs were particularly interesting. 
Annotations in PlasmoDB mentioned that 11 of the 34 genes to analyse had 
transmembrane domains. Of these 11 genes, seven were particularly interesting 
since the putative protein expressed by these genes had at least two predicted 
transmembrane domains. The five genes were MAL7P1.16, MAL7P1.17, 
PF07_0016, MAL7P1.19, PF07_0018, MAL7P1.340, and MAL7P1.205 (Table 3.5.). 
MAL7P1.19 was annotated in PlasmoDB as putative ubiquitin transferase and 
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MAL7P1.340 as ATP synthase subunit c, putative. The functions of the others, 
though, were still unknown. Basic BLAST search to find sequence similarity between 
the genes with unknown function with functionally understood genes also failed to 
give satisfactory results with the appropriate S and E values. 
For most of the five putative proteins, apart from MAL7P1.19, the number of TMDs 
determined by TMHMM method (Krogh et al., 2001) were in agreement with the 
number annotated at PlasmoDB. For this MAL7P1.19 protein, PlasmoDB showed 
only four TMDs, whereas the TMHMM method predicted the presence of six TMDs. 
 
Table 3.5. Candidate genes having TMD that are located within B5M12 peak. 
All of them are expressed during the trophozoite stage  
ER: Early Rings; LR: Late Rings; ET: Early Trophozoites; LT: Late Trophozoites; ES: Early 
Schizonts; LS: Late Schizonts; M: Merozoites; *: as annotated in PlasmoDB 
Gene 
 Expression 
Pattern* 
 Annotated 
Name/Function* 
 TMDs 
MAL7P1.16 
 Expressed in ER, ET, and 
LT 
 conserved Plasmodium 
membrane protein, 
unknown function 
 8 
MAL7P1.17 
 
from LT onwards 
 conserved Plasmodium 
membrane protein, 
unknown function 
 7 
PF07_0016 
 Expressed throughout 
intra-erythrocytic stage 
 conserved Plasmodium 
membrane protein, 
unknown function 
 
4 
MAL7P1.19 
 Expressed throughout 
intra-erythrocytic stage 
 putative ubiquitin 
transferase 
 4 (K&D) 
6 (TMHMM)
PF07_0018 
 Expressed throughout 
intra-erythrocytic stage 
 conserved Plasmodium 
membrane protein, 
unknown function 
 
7 
MAL7P1.340  Unknown  putative ATP synthase subunit c  
 2 
MAL7P1.205 
 Expressed at the same 
level throughout the 
intraerythrocytic stage
(Dd2) 
Expressed throughout the 
intraerythrocytic stage, 
with peak in ET (HB3) 
 conserved Plasmodium 
protein, unknown function 
  
 
3 
 
Database analysis showed that MAL7P1.16 and MAL7P1.17 were expressed during 
trophozoite stage of the parasite, whereas the other three were expressed 
constitutively during intraerythrocytic life cycle. These expression patterns were in 
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agreement with the common belief that quinoline drugs act by interfering with haem 
detoxification in the food vacuole (Hawley et al., 1998), which presents only from 
trophozoite stage onwards. 
Searching for polymorphisms of these candidate genes in Dd2 and HB3 though 
productive was not reliable. The Dd2 sequence was incomplete at the time of the 
analysis that it was difficult to decide whether the polymorphisms found were genuine 
or due to poor sequencing. 
3.5.2. Analysis of VAPA Peak 
 
The verapamil sensitive VAPA peak located in chromosome 13 was present 
specifically in the primary scan of QN IC90. This part of the chromosome did not seem 
to affect QN accumulation, since the peak did not come out in QTL analysis on the 
drug accumulation.  
The peak spanned over seven markers (five markers lie within area with the highest 
LOD score plus two flanking markers). According to NCBI data base, there were 71 
genes located within these markers. However, newer annotation by PlasmoDB 
showed that eight of these genes were in fact located elsewhere in the chromosome 
whereas two others did not exist at all, thus leaving only 61 genes positioned within 
these markers.  
BLAST analysis of these 61 genes using Broad Institute MIT Database led to the 
finding that 14 of these genes were completely conserved in Dd2 and HB3, thus 
excluding them from possible candidates. In addition to that, the BLAST search 
showed that there were three genes where a small part of either Dd2 or HB3 
sequences were incomplete, but showing no polymorphism at all in the part that had 
been sequenced. The absence of polymorphisms in these genes, however, had to be 
further proven by thoroughly re-sequencing the genes. There was also a gene 
named MAL13P1.45, where the only polymorphism between Dd2 and HB3 was a 
deletion of an asparagine (N) residue from position 661 in Dd2. This residue, 
however, lies in an N-rich area, that the apparent deletion might be a mere 
sequencing error. Apart from this gene, there was also PF13_0070 gene, which only 
polymorphism between Dd2 and HB3 was an R429P substitution at the last amino 
acid. Since this amino acid position is prone to sequencing error, it would probably be 
necessary to perform new sequencing to ensure whether this polymorphism was real 
or merely an artefact. 
The number of candidate genes was further reduced when analysing the expression 
pattern of these genes as annotated in PlasmoDB, since some genes were only 
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expressed in late schizont (LS) and gametocyte (G) stages. Some others were not 
expressed at all during intraerythrocytice cycle. Bearing in mind that QN, like other 
quinoline drugs, acts by interfering with haem detoxification in the food vacuole 
(Hawley et al., 1998), these genes could not have affected the QN IC90.  
Analysis of TMDs led to 6 proteins with 2, 6 and 14 transmembrane domains. 
PlasmoDB also annotated the same number of TMD in these proteins (listed in Table 
3.6.). From these genes only PF13_0077 was annotated with a known function. The 
other four genes, MAL13P1.49, MAL13P1.50, PF13_0078 and MAL13P1.70 were 
Basic Blast searched to find sequence similarities with genes of known functions. 
However, the search failed to find any hits with suitable S and E values. 
 
Table 3.6. Candidate genes located within VAPA peak. 
All of them are expressed during the trophozoite stage  
ER: Early Rings; LR: Late Rings; ET: Early Trophozoites; LT: Late Trophozoites; ES: Early 
Schizonts; LS: Late Schizonts; M: Merozoites 
Gene 
 Expression 
Pattern* 
 Annotated 
Name/Function* 
 TMDs
MAL13P1.49 
 constitutively expressed, peak 
in ES and LS 
 hypothetical protein, 
conserved 
 2 
MAL13P1.50 
 constitutively expressed, peak 
at LT and ES 
 hypothetical protein, 
conserved 
 2 
PF13_0077 
 
From LR to LS 
 DEAD box helicase, 
putative 
 2 
PF13_0078 
 
LR, LT, ES, LS, M 
 hypothetical protein, 
conserved 
 14 
MAL13P1.70 
 
ET, LT 
 hypothetical protein, 
conserved 
 6 
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4. Discussions 
 
In this project, QTL analysis based on QN accumulation data showed that the initial 
accumulation of QN is genetically linked to two major factors, pfcrt and a factor 
located within the area of B5M12 peak as shown in Figure 3.5. The factor located in 
B5M12 seems to act synergistically with pfcrt in reducing QN accumulation (Figure 
3.8.). The reanalysis of the published Ferdig’s QN IC90 data indicated that both of 
these loci also synergistically increased QN IC90 (Figure 3.8.), hence reducing the 
drug sensitivity. In addition, the reanalysis of the QN IC90 also indicated the 
involvement of two QTL on chromosome 13 (Figure 3.5.), which were already 
reported previously (Ferdig et al., 2004). These QTL do not seem to affect QN 
accumulation, thus, might encode for a target of QN. 
Unlike CQ, the mechanisms of QN accumulation, action and resistance are not well 
understood, despite the numbers of research and discovery related to it. Studies 
have also shown that QN and CQ resistances share the same factor, that is pfcrt 
(Ferdig et al., 2004), and mutation within this gene results in reduced sensitivity in 
CQ and QN (Cooper et al., 2007, Lakshmanan et al., 2005, Johnson et al., 2004). 
However, in their publication Sen and Ferdig pointed out that unlike CQ resistance, 
which is determined by only a single factor (Sen & Ferdig, 2004), pfcrt (Ferdig et al., 
2004), QN sensitivity shows a pattern typical of that of a multifactorial trait (Sen & 
Ferdig, 2004).  
Due to its multifactorial determinants, QTL analysis has been used to understand QN 
mechanisms. Ferdig et al. used QTL analysis of Dd2xHB3 cross QN IC90 data to 
determine loci related to QN sensitivity levels (Ferdig et al., 2004). The results of 
Ferdig’s study identified two major QTL in the primary scan, the pfcrt locus on 
chromosome 7 and a locus in chromosome 13, closed to pfnhe. In the secondary 
scan, they identified a locus located close to pfmdr1 on chromosome 5.  
Despite the association between several loci with QN resistance as shown by Ferdig 
et al. in their publication (Ferdig et al., 2004), a recent publication shows that reduced 
accumulation of QN is not always accompanied with increased QN resistance 
(Sanchez et al., 2008b). Since IC90 is a measure of cell proliferation inhibition after 72 
hours of exposure to a drug, it might be influenced by other factors in addition to 
those affecting only the initial drug accumulation property. Whilst initial drug 
accumulation is affected by only partitioning and transport processes, IC90 might also 
be influenced by mutation and availability of the drug target, or even the combination 
of both mutation at the target and the transport machinery. Thus, measuring initial 
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QN accumulation leads to obtaining a readout defined by only transport mechanism, 
whilst eliminating the effect of other processes causing cell death. 
In this study, Ferdig’s IC90 data were reanalysed using the same QTL method to 
ensure the comparability of the different sets of data. In parallel to measuring and 
performing QTL analysis on QN accumulation, CQ accumulation was also measured 
and the QTL analysis of its initial accumulation was also performed as a mean of 
proving the validity of the method (Mayer, 2009). As predicted, QTL analysis of CQ 
initial accumulation was linked to a single factor affecting CQ accumulation (Mayer, 
2009), hence proving the validity of the approach. 
In this study, three stages of QTL analysis were performed. In the primary scan, 
major factors affecting the phenotypic trait were investigated. Loci obtained in the 
primary scans greatly affect the accumulation or IC90. The secondary scans, on the 
other hand, explored factors affecting variations within two different groups of strains, 
the CQR and CQS strains. These factors might not have significant effect to the 
overall variation of the strains, and therefore might not be obvious in the primary 
scans, since their effect might be masked by the presence of the major factors. The 
third stage of QTL analysis performed in this study is mathematically analysing the 
interaction between positive loci found in the primary and secondary scans. 
In addition to reanalysing Ferdig’s QN IC90 data, Ferdig’s data on QN IC90 with the 
presence of verapamil (Ferdig et al., 2004) was also reanalysed. Verapamil is known 
to reverse CQ resistance caused by pfcrt mutation (Wellems et al., 1990, Martin et 
al., 1987). Although reduced accumulation of QN does not always correlate to 
increased QN resistance (Sanchez et al., 2008b), all strains having K76T mutated 
pfcrt show increased verapamil-sensitive QN efflux (Sanchez et al., 2008b). Thus 
comparing the data of QN IC90 QTL analyses with and without the presence of 
verapamil should lead to discovering factors affecting QN IC90 other than pfcrt, if any, 
which effect is reversed by verapamil. 
This study shows that reduced initial quinine accumulation is genetically linked to 
both pfcrt and a novel QTL corresponding to B512 marker in chromosome 7 (Figure 
3.5.). Both loci have negative effect to QN accumulation. The reanalysis of Ferdig’s 
QN IC90 data indicated that both loci also contribute to the increased QN IC90 value, 
hence reducing the sensitivity. Lower LOD score obtained in the original study of QN 
IC90 performed by Ferdig’s group (Ferdig et al., 2004), leading to poor resolution of 
the two loci, is the underlying reason why they had failed to observe the significant 
effect of B5M12 locus. 
The mathematical analysis shows that Dd2 allele of B5M12 only affects the QN 
accumulation and IC90, when pfcrt is also from Dd2, that is, in CQR strains but not in 
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CQS strains (Figure 3.8.), suggesting that the presence of Dd2 alleles at both loci act 
synergistically reducing accumulation and increasing IC90. 
 
 
Figure 4.1. Some allelic exchange mutants, with the genetic background of 
GC03 strain and having Dd2 pfcrt allele introduced to them, exhibited a 
decreased QN IC50 values, in comparison to GC03 (Sanchez et al., 2008b) (A) 
and the presence of Dd2 allele at pfcrt locus is not the only prerequisite of 
acquiring QN accumulation and IC90 levels comparable to that of Dd2 (B). 
C2GC03 has GC03 background with autologous HB3-like pfcrt allele. C4Dd2 has GC03 
background with Dd2-like pfcrt allele. 
 
Ferdig’s QN IC90 data demonstrated that several F1 progeny of the Dd2xHB3 cross 
having Dd2 pfcrt displayed QN IC90 values comparable to that of HB3, the QN 
sensitive parent (see Apendix 3) (Ferdig et al., 2004). In addition, Sanchez et al. 
demonstrated in their publication that some allelic exchange mutants having Dd2 
pfcrt allele introduced to them with the genetic background of GC03 strain exhibited a 
decreased QN IC50 values, in comparison to GC03 (Figure 4.1.) (Sanchez et al., 
2008b). Originally, GC03 has inherited both its pfcrt and B5M12 from HB3 (Su et al., 
1999). The phenomena observed by Ferdig’s and Sanchez’s groups can be 
explained partly by the involvement of B5M12 as a major factor affecting QN 
accumulation and IC90 and the synergistic effect of pfcrt and B5M12. The analysis 
performed in the current study demonstrated that the presence of Dd2 allele at pfcrt 
locus is not the only prerequisite of acquiring QN accumulation and IC90 levels 
comparable to that of Dd2. The average QN accumulation and IC90 values of strains 
with different combinations of pfcrt and B5M12 are tabulated in Figure 4.1. 
Despite the database search performed, the responsible gene lying within the B5M12 
locus is not yet identified. Within the locus, 41 genes were annotated in PlasmoDB 
 
 
 Accumulation IC90 
Dd2 115.89 925 
HB3 168.49 382 
 
Origin of 
B5M12 pfcrt
Accumulation 
(mean ± SE) 
IC90 
(mean ± SE) 
H H 182.8±4.8 385.4±33.8 
D H 181.1±37.7 290.5±91.5 
H D 166.8±13.3 456.7±46.8 
D D 123.1±4.1 642.1±66.1 
    
A B
                                                                                                                    Discussions 
 78 
and NCBI gene bank, of which four were tRNA genes, leaving 34 genes possible 
candidates. A comparison of the corresponding genomic sequences from HB3 and 
Dd2 identified putative polymorphisms in 32 of the genes. Seven of these genes 
encode for proteins with at least two TMDs (Table 3.5.). Physical interaction between 
PfCRT and a protein encoded within the B5M12 is a possibility, since there are 
examples of interaction between different subunits of plant transporters (Reinders et 
al., 2002), mammalian transporters (Sun et al., 2007), and bacteria (Ames, 1976). 
Yet, unavailability of complete sequences within the region had rendered it 
impossible to point specifically at certain candidates. Further sequencing revealing 
polymorphisms within this region should be attempted to be able to answer the 
question. 
In the primary scan reanalysis of Ferdig’s QN IC90 data, two additional positive loci 
were found in chromosome 13 (Figure 3.5.), which LOD scores were almost as high 
as those of B5M12 and pfcrt. The positive loci are correlated to markers VAPA and 
C13M73. Despite their high LOD scores for QN IC90, these loci showed no influence 
to QN accumulation. This specific character of the loci would not have been revealed 
had the QTL analysis based on QN accumulation data not been performed. 
Ferdig’s group had considered the two significant peaks in chromosome 13 as only 
one QTL called C13M56 and that the putative pfnhe gene, which had been 
implicated in altered QN responsiveness (Bennett et al., 2007), might be present 
within the area (Ferdig et al., 2004). In the reanalysis, however, it was clear that 
these two peaks corresponded to two functionally separable loci with different 
responsiveness to verapamil. The left hand VAPA peak was completely diminished 
by the presence of verapamil, whereas the right hand C13M73 peak was relatively 
verapamil insensitive (Figure 3.5.).  
In addition, the reanalysis also revealed that the TA46 marker, which contains the 
putative pfnhe gene, is located in neither of these two peaks. Instead, the marker 
mapped to the valley between the two peaks, clearly outside of the two QTL (Figure 
3.5.). 
The involvement of extended repeat polymorphisms within PfNHE in increased QN 
resistance, as reported previously (Ferdig et al., 2004, Bennett et al., 2007, Nkrumah 
et al., 2009), might therefore be mediated by mechanisms at later time point than the 
commencement of the initial QN accumulation.  
The facts that the two loci (VAPA and C13M73) involved only in QN IC90 but not in 
QN accumulation suggested that they were targeted by QN, instead of affecting QN 
transport. Mathematical analysis showed that the presence of Dd2 allele at these loci 
is associated with higher QN IC90 value (Figures 3.11. (B) and 3.12. (B)), 
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independent of the origins of the pfcrt and B5M12. Thus, it seemed that the Dd2 
alleles at these loci have additive effect to the QN IC90. 
So far, verapamil ability to reverse CQ and QN resistance has been attributed to the 
reversal of the K76T mutation of pfcrt (Lakshmanan et al., 2005). However, the 
discovery of the verapamil sensitive VAPA peak, which could be targeted by QN, 
might lead to understanding an additional role of verapamil in reducing the IC90. It 
was, however, published previously that quinine and verapamil showed synergistic 
chemosensitisation of multidrug resistant tumour cells (Lehnert et al., 1991), that it is 
tempting to speculate whether they could compete for the same target. 
The genes encoding for this putative QN target remain to discover. Exploration of 
databases reveals 61 genes lying within the VAPA peak, of which 14 showed no 
polymorphisms between Dd2 and HB3. Incomplete data available at the online 
database had been a real obstacle that had yet to be overcome by thorough 
sequencing of the area under the peak. 
The secondary scan revealed the association of peaks with minor effect to the 
phenotypes. These peaks were not obvious in the primary scan because their 
presence were overshadowed by the effects of the major peaks found in the primary 
scan. 
The secondary scans showed association between the peaks containing pfmdr1 to 
both QN accumulation and IC90. Interestingly, the Dd2 allele of the locus seemed to 
contribute to an increase in initial QN accumulation and to the decrease of QN IC90. 
The involvement of PfMDR1 as well as its role in drug resistance has been much 
studied, however, how the protein works remains obscure. PfMDR1 resides in the 
FVM, with its ATP binding domains facing the parasite cytosol (Karcz et al., 1993), 
and thus might allow import of solutes from the cytosol to the FV.  A publication by 
Rohrbach et al. showed that subcellular distribution of a fluorescent indicator 
consistent with the view that the PfMDR1 indeed imported solutes into the FV and 
the import function is influenced by pfmdr1 polymorphisms that affect antimalarial 
drug sensitivity (Rohrbach et al., 2006). The protein also seems to transport a range 
of solutes across the FVM (Saliba et al., 2008). Sanchez et al. used pfmdr1-
expressing Xenopus laevis oocytes to show that polymorphisms at this gene brought 
about substantial differences in the transport of pharmaceuticals, including quinine 
(Sanchez et al., 2008a). Thus, it is not improbable that it is, indeed, the pfmdr1 gene 
on chromosome 5 that in the Dd2 version pumps QN into the FV, this bringing about 
the increased sensitivity to quinine.  
Another positive locus found in the secondary scan of QN IC90 was BM75. The locus 
was located in chromosome 7. This locus is located at the same cM position as 
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B5M74 locus, which is described in Ferdig’s publication as interacting with pfcrt and 
that the inheritance of the Dd2 alleles at both B5M74 and pfcrt loci resulted in 
substantially higher QN IC90 values than inheritance of other possible allele 
combinations (Ferdig et al., 2004).  
Analysis of BM75 demonstrated that the presence of Dd2 allele at both pfcrt and 
BM75 loci was a must for the significant increased of QN IC90, indicating that these 
allele have synergistic effect to the IC90 phenotype. Since BM75 peak was not 
present in the secondary scan of QN accumulation, it make sense that the locus 
showed no significant difference in QN accumulation level with all allelic 
combinations at the BM75 and pfcrt loci (Figure 3.12. (A)). 
C5M2 was another locus appeared in the secondary scan. This locus is the only 
accumulation specific locus discovered in the secondary scan on CQS strains. As 
predicted by the QTL analysis and confirmed by further analysis mathematically, the 
locus seemed to affect QN accumulation variation in CQS strains only, without 
showing any observable effect to IC90 (Figure 3.13.). 
In conclusion, the study has proven that the strain specific variation of initial QN 
accumulation and degree of resistance are clearly controlled by multiple genetic 
factors. The analysis of QN accumulation has managed to reveal novel loci linked to 
initial QN accumulation level, which were not previously identified by QTL analysis 
using QN IC90 data. Having obtained better LOD scores from the reanalysis of QN 
IC90 data, peaks with better resolution than the ones originally published by Ferdig 
(Ferdig et al., 2004) were obtained. In addition to pfcrt, B5M12 seems to be a major 
factor in both QN accumulation and IC90 and act synergistically with pfcrt.  
Two other loci, VAPA and C13 M73, which are located in chromosome 13 seem to 
have major roles in QN IC90, but not accumulation. These loci were not likely to be 
resolved from factors affecting QN accumulation, had no QTL analysis of QN 
accumulation been performed. These two loci act independently from the major loci 
in chromosome 7 and have additive effect related to the Dd2-alleles.  
The secondary scans performed separately on CQR and CQS strains managed to 
reveal minor factors affecting the phenotypes. Peaks containing pfmdr1 gene were 
found to be associated to both QN accumulation and IC90. It was really intriguing, 
however, to find that the Dd2 allele of the locus seemed to contribute to an increase 
in initial QN accumulation and to the decrease of QN IC90. However, the 
phenomenon that PfMDR1 imports solute into the FV was also observed previously 
(Rohrbach et al., 2006). 
Although the study has discovered various loci linked to QN accumulation and 
resistance, detailed investigation, locus by locus, separately or in combination to one 
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another, is essential to find the specific underlying gene responsible for the 
phenotypes and to understand the exact mechanisms of the accumulation and its 
relation to resistance. 
Some of the minor loci revealed in the secondary scans, for example BM75, seemed 
to interact with major loci such as pfcrt. It would be interesting, had time permitted it 
to study, locus-by-locus, the interactions of the positive loci to one another. 
So far, the major obstacle in finding specifically the responsible genes in the loci is 
the unavailability of complete sequences of Dd2 and HB3, let alone the progeny, in 
the databases. Thus, following the in silico dissection of the positive loci by searching 
available databases in order to find candidate genes, in vitro sequencing of the 
parental strains (Dd2 and HB3), especially within the areas under the positive loci, 
should be performed followed by analysis of the presence of polymorphisms within 
the area. Polymorphisms within these areas might be related to the different 
phenotypes expressed by the strains. Prediction of protein conformation and 
presence of transmembrane domains in the putative proteins might lead to discovery 
of new transport proteins related to the accumulation of the drugs. Functional studies 
of the putative proteins can then be performed by expressing the mRNA of the 
putative gene in Xenopus laevis oocytes to see the activity of the putative proteins. 
Generation of mutants with knocked-out the candidate genes might be a useful 
approach to see what the effects and the functions might be. 
In short, plenty of works await still to be done before the thorough understanding of 
the complete mechanisms behind QN accumulation and resistance might be 
acquired. 
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6. Appendices 
 
 
  
Appendix 1. Ferdig’s QTL analysis of QN IC90 and QN-VP IC90 (Ferdig et al., 
2004) 
(A) QN IC90 primary scan and (B) secondary scan, after removing the effect of pfcrt (C) QN-
VP IC90 primary scan 
C 
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B5M12 and pfcrt  
from HB3 
B5M12 from Dd2 
pfcrt from HB3 
B5M12 from HB3 
pfcrt from Dd2 
B5M12 and pfcrt  
from Dd2 
Strains Accum. IC90  Strains Accum. IC90  Strains Accum. IC90  Strains Accum. IC90 
HB3 168.49 382  C188 218.82 382  TC05 141.43 378  Dd2 115.89 925 
B1SD 223.27 328  CH3-116 143.37 199  D43 186.41 452  3BA6 111.55 1038 
QC13 213.88 539      7C111 172.44 540  1BB5 106.75 1044 
QC01 168.68 456          3BD5 156.52 379 
B4R3 203.91 202          SC01 144.57 736 
SC05 202.56 428          QC34 110.25 673 
TC08 184.35 262          QC23 119.92 528 
GC03 169.16 351          GC06 115.97 755 
CH3-61 159.39 322          C408 107.42 760 
7C3 191.01 732          7C12 119.95 436 
7C7 188.91 485          7C46 121.95 625 
7C126 175.71 289          7C183 122.73 380 
7C140 175.02 217          7C421 145.68 388 
7C159 184.66 542          7C424 124.12 322 
7C170 148.54 262             
7C16 185.50 287             
7C20 164.29 468             
Appendix 2. The QN accumulation and IC90 levels of strains grouped based on 
their inheritance of B5M12 and pfcrt. 
